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ABSTRACT 
 
 
It has now become evident that insulin exerts a direct action on vascular cells, 
thereby conditioning the outcome and progression of vascular complication 
associated with diabetes. However, the mechanisms through which insulin 
signaling is impaired in the vascular endothelium remain still unclear. Chronic 
hyperglycaemia per se promotes insulin resistance and plays a pivotal role in the 
outcome and progression of diabetes-associated vascular complications. 
Hyperglycaemia may act through different mechanisms, including generation of 
advanced glycation end products (AGEs). In this work we evaluated the role of the 
AGEs precursor methylglyoxal (MGO) in the generation of endothelial insulin-
resistance in cellular and animal models. 
Time-courses experiments were performed on bovine aortic endothelial cells 
(BAEC) incubated with different concentrations of MGO. The glyoxalase 1 
inhibitor “SpBrBzGSHCp2” was used to increase the endogenous levels of MGO. 
For the in vivo study, C57bl6 mice were intraperitoneally injected with a MGO 
solution at steadily increasing concentrations (50 to 75mg/kg) for 7 weeks. 
MGO incubation induces a 50% reduction of IRS1 phosphorylation, the loss of 
IRS1-p85 interaction and of the downstream Akt activation in response to insulin, 
whilst MAPK is more active in BAEC treated with MGO. The insulin-induced Akt 
activation is reverted by the inhibition of ERK through the use of MEK inhibitor 
U0126 in BAEC treated with MGO. Furthermore, downstream Akt, MGO is able 
to inhibit eNOS activation in response to insulin, and this was paralleled by a 60% 
decrease of insulin-induced NO production in BAEC. Similar results were 
obtained in BAEC treated with SpBrBzGSHCp2 compared to controls. 
Intraperitoneally administration of MGO to mice caused insulin resistance (ITT 
AUC: C57MGO 10163±1979 vs C57 7787±1174 mg/dl/120’, p=0.01) and reduced 
serum NO by 2.5-fold compared to untreated mice. Western blots of lysates of 
aortae from MG-treated mice revealed a reduction of insulin-induced Akt 
activation. 
In conclusion, this work shows that MGO impairs insulin signaling in 
endothelial cells and insulin effect on endothelial NO production both in vitro and 
in vivo. A possible role in these effects may be played by ERK. Further 
investigations of the molecular mechanisms by which hyperglycaemia 
compromises insulin action in vascular cells may allow to develop new strategies 
to preserve endothelial function in diabetic subjects. 
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Abbreviations: 
 
AGE       Advanced Glycation End products 
AKT/PKB  protein kinase B 
CEL   Nε-carboxyethyl-lysine  
CML    Nε-carboxymethyl-lysine  
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GSH    Glutathione  
HGA    Human Glycated Albumin  
IR    Insulin Receptor  
IRS    Insulin-Receptor Substrate  
JNK   Jun N-terminal Kinase  
MAP    Mitogen Activated Protein  
MGO    Methylglyoxale 
N-GlcNAc  N-Acetyl Glucosamine 
NO    Nitric Oxide  
PI3K   Phosphatidyl Inositol 3-Kinase 
PKC    Protein Kinase C  
RAGE   Receptor for Advanced Glycation End products  
ROS    Radical Oxygen Species 
SpBrBzGSH   Bromobenzylglutathione cyclopentyl diester 
T1D   Type 1 Diabetes 
T2D   Type 2 Diabetes 
vSMC   vascular Smooth Muscle Cells  
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BACKGROUND 
 
 
1.1 Insulin Resistance: a common feature of different metabolic 
disorders and their complications. 
 
Insulin resistance plays a major patho-physiological role in type 2 diabetes and  
is tightly associated with major public health problems including obesity, 
hypertension, coronary artery disease, dyslipidemias, and a cluster of metabolic 
and cardiovascular abnormalities that define the metabolic syndrome (De Fronzo 
and Ferrannini 1991; Petersen et al. 2007). Insulin resistance is defined clinically 
as the inability of a known quantity of exogenous or endogenous insulin to 
produce its biological effects, as the increase of glucose uptake and utilization. 
Several mechanisms have been proposed as possible causes underlying the 
development of insulin resistance and the insulin resistance syndrome. These 
include: genetic abnormalities of one or more proteins of the insulin action 
cascade, fetal malnutrition and increases in visceral adiposity (Lebovitz et al. 
2001).   
As reported above, insulin-resistance is a hallmark of type 2 diabetes, a complex 
heterogeneous group of metabolic conditions characterized by elevated levels of 
serum glucose and resulting from defects in both insulin secretion and insulin 
sensitivity. It is associated with an increased and premature risk of cardiovascular 
disease as well as specific microvascular complications, including retinopathy, 
nephropathy, and neuropathy (Srinivasan et al. 2008). Type 2 diabetes 
pathogenesis results from interactions of a number of genes with environmental 
factors such as obesity, age, and nutrition. Multiple prospective studies have 
documented an association between insulin resistance and accelerated 
cardiovascular disease (CVD) in patients with type 2 diabetes. The molecular 
causes of insulin resistance are responsible for the impairment in insulin-
stimulated glucose metabolism and contribute to the accelerated rate of CVD in 
type 2 diabetes patients. The current epidemic of diabetes is being driven by the 
obesity epidemic, which represents a state of tissue fat overload. Accumulation of 
toxic lipid metabolites (fatty acyl CoA, diacylglycerol, ceramides) in muscle, liver, 
adipocytes, beta cells and arterial tissues contributes to insulin resistance, beta cell 
dysfunction and accelerated atherosclerosis in type 2 diabetes (DeFronzo et al. 
2010). These complex metabolic disorders are complicated by vascular disease 
(De Fronzo et al. 2009). Hyperglycaemia is the major risk factor for microvascular 
complications (Stratton et al. 2000). Hyperglycaemia toxic effects regard above all 
those tissues in which cellular glucose uptake is insulin-independent and that are 
unable to block glucose entrance, like retina, kidney, blood vessels and nerves 
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(Schleicher and Nerlich 1996). Thus, the metabolic alterations caused by 
hyperglycaemia affect different cell types, leading to both macrovascular and 
microvascular dysfunctions (Tooke 1995), and involving all the vascular tissue 
components together with circulating cells that infiltrate the vascular wall itself. 
Diabetic microangiopaty involves all body districts, although it leads to typical 
morphological features, regarding the specific organ structures and functions such 
as retina, nerves and renal glomeruli. Diabetic macroangiopaty consists on 
macrovascular damage of heart, brain and lower extremities arteries.  
Although microvascular complications are a major cause of morbidity, 
macrovascular complications represent the primary cause of mortality with heart 
attacks and stroke accounting for around 80% of all deaths (Morrish et al. 2001). 
Diabetes mellitus is commonly associated with systolic/diastolic hypertension. 
Much evidence indicates that the link between diabetes and essential hypertension 
is hyperinsulinemia. The reasons for the association of insulin resistance and 
essential hypertension can be sought in at least four general types of mechanisms: 
Na+ retention, sympathetic nervous system overactivity, disturbed membrane ion 
transport, and proliferation of vascular smooth muscle cells. Calorie restriction (in 
the overweight patients) and regular physical exercise, can improve tissue 
sensitivity to insulin and lower blood pressure in both normotensive and 
hypertensive individuals. Insulin resistance and hyperinsulinemia are also 
associated with an atherogenic plasma lipid profile. Elevated plasma insulin 
concentrations enhance very-low-density lipoprotein (VLDL) synthesis, leading to 
hypertriglyceridemia. Progressive elimination of lipid and apolipoproteins from 
the VLDL particle leads to an increased formation of intermediate-density and 
low-density lipoproteins, both of which are atherogenic. Last, insulin, independent 
of its effects on blood pressure and plasma lipids, is known to be atherogenic. The 
hormone enhances cholesterol transport into arteriolar smooth muscle cells and 
increases endogenous lipid synthesis by these cells. Insulin also stimulates the 
proliferation of arteriolar smooth muscle cells, augments collagen synthesis in the 
vascular wall, increases the formation of and decreases the regression of lipid 
plaques, and stimulates the production of various growth factors (DeFronzo et al. 
1991). 
Together with type 2 diabetes, obesity rapresents an important risk factor for the 
development of cardiovascular diseases (Kearney et al. 2007). Nowadays, the 
adipose tissue is considered as an endocrine organ able to produce substances 
called adipo(cyto)kines that have different effects on lipid metabolism, closely 
involved in metabolic syndrome, and cardiovascular risk. The increased 
cardiovascular risk can be related also to peculiar dysfunction in the endocrine 
activity of adipose tissue observed in obesity responsible of vascular impairment 
(including endothelial dysfunction), prothrombotic tendency, and low-grade 
chronic inflammation (Maresca et al. 2011). In the setting of obesity, the over-
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production of proinflammatory and pro-thrombotic adipokines is associated with 
insulin resistance. This mechanism represents the pathophysiological basis for the 
development of metabolic syndrome (Espinola-Klein et al. 2011). Excess fat, also 
deposited in visceral organs, generates chronic low-grade inflammation that 
eventually triggers insulin resistance and the associated comorbidities of metabolic 
syndrome (hypertension, atherosclerosis, dyslipidaemia and diabetes mellitus). 
The perivascular adipose tissue has a paracrine function, including the release of 
adipose-derived relaxant and contractile factors, akin to the role of the vascular 
endothelium, and contributing to the cardiovascular pathophysiology of the 
metabolic syndrome (Achike et al. 2011). 
 
 
 
Figure 1: Metabolic and cardiovascular complications related to metabolic syndrome. 
 
 
1.1.1 Insulin action. 
 
Insulin is the most potent anabolic hormone known. Secreted by pancreatic beta 
cells in response to the increase in plasmatic glucose and amino acids levels after 
feeding, insulin promotes the synthesis and storage of carbohydrates, lipids and 
proteins, while inhibiting their degradation and release into the circulation. Insulin 
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stimulates the uptake of glucose, amino acids and fatty acids into cells, and 
increases the expression and the activity of enzymes that catalyse glycogen, lipid 
and protein synthesis, while inhibiting the activity or the expression of those that 
catalyse degradation. Insulin increases glucose uptake in muscle and fat, and it 
inhibits hepatic glucose production (glycogenolyisis and gluconeogenesis) in liver, 
thus serving as the primary regulator of blood glucose concentration. Insulin also 
stimulates cell growth and differentiation, and promotes the storage of substrates 
in fat, liver and muscle by stimulating lipogenesis, glycogen and protein synthesis, 
and inhibiting lipolysis, glycogenolysis and protein breakdown (Figure 1) (Saltiel 
and Kahn 2001).  
 
 
 
Figure 2: The regulation of metabolism by insulin. Insulin promotes the synthesis and the 
storage of carbohydrates, lipids and proteins. Indeed, insulin stimulates the uptake of glucose, 
amino acids and fatty acids into cells, and increases the expression or the activity of enzymes that 
catalyse glycogen, lipid and protein synthesis, while inhibiting the activity or the expression of 
those that catalyse degradation. 
 
 
Insulin action is mediated through the insulin receptor (IR), a transmembrane 
glycoprotein with intrinsic protein tyrosine kinase activity. The insulin receptor 
belongs to a subfamily of receptor tyrosine kinases that includes the insulin-like 
growth factor (IGF)-I receptor and the insulin receptor-related receptor (IRR). 
These receptors are tetrameric proteins consisting of two α- and two β-subunits 
that function as allosteric enzymes where the α-subunit inhibits the tyrosine kinase 
activity of the β-subunit. Insulin binding to the α-subunit leads to derepression of 
the kinase activity of the β-subunit followed by transphosphorylation of the β-
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subunits and conformational change of the α subunits that further increases kinase 
activity. Several intracellular substrates of the insulin receptor kinases have been 
identified (Figure 2). Four of these belong to the family of insulin-receptor 
substrate (IRS) proteins (White et al. 1998). Other substrates include Gab-1 and 
isoforms of Shc10 (Pessin and Saltiel 2000). The phosphorylated tyrosines in these 
substrates act as ‘docking sites’ for proteins that contain SH2 (Src homology-2) 
domains. Many of these SH2 proteins are adaptor molecules, such as the p85 
regulatory subunit of PI(3)K and Grb2, or CrkII, which activate small G proteins 
by binding to nucleotide exchange factors. Others are themselves enzymes, 
including the phosphotyrosine phosphatase SHP2 and the cytoplasmic tyrosine 
kinase Fyn. PI(3)K has a pivotal role in the metabolic and mitogenic actions of 
insulin (Shepherd et al. 1995). It consists of a p110 catalytic subunit and a p85 
regulatory subunit that possesses two SH2 domains that interact with 
tyrosinephosphorylated motifs in IRS proteins (Myers MG Jr 1992). PI(3)K 
catalyses the phosphorylation of phosphoinositides on the 3-position to produce 
phosphatidylinositol-3-phosphates, especially PtdIns(3,4,5)P3, which bind to the 
pleckstrin homology (PH) domains of a variety of signalling molecules thereby 
altering their activity, and subcellular localization (Lietzke et al. 2000). 
Phosphotidylinositol-3-phosphates regulate three main classes of signalling 
molecules: the AGC family of serine/threonine protein kinases, the Rho family of 
GTPases, and the TEC family of tyrosine kinases. PI(3)K also might be involved 
in regulation of phospholipase D, leading to hydrolysis of phosphatidylcholine and 
increases in phosphatidic acid and diacylglycerol. The best characterized of the 
AGC kinases is phosphoinositide-dependent kinase 1 (PDK1), one of the serine 
kinases that phosphorylates and activates the serine/threonine kinase Akt/PKB 
(Alessi et al. 1997). Akt/PKB has a PH domain that also interacts directly with 
PtdIns(3,4,5)P3, promoting membrane targeting of the protein and catalytic 
activation. Akt/PKB has a pivotal role in the transmission of the insulin signal, by 
phosphorylating the enzyme GSK-3, the forkhead transcription factors and cAMP 
response element-binding protein. Other AGC kinases that are downstream of 
PI(3)K signaling include the atypical PKCs, such as PKC-ζ. Akt/PKB and/or the 
atypical PKCs are required for insulin stimulated glucose transport (Standaert et al. 
1997).  
As is the case for other growth factors, insulin stimulates the mitogen activated 
protein (MAP) kinase extracellular signal regulated kinase (ERK) (Figure 2). This 
pathway involves the tyrosine phosphorylation of IRS proteins and/or Shc, which 
in turn interact with the adapter protein Grb2, recruiting the Son-of-sevenless 
(SOS) exchange protein to the plasma membrane for activation of Ras. The 
activation of Ras also requires stimulation of the tyrosine phosphatase SHP2, 
through its interaction with receptor substrates such as Gab-1 or IRS1/2. Once 
activated, Ras operates as a molecular switch, stimulating a serine kinase cascade 
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through the stepwise activation of Raf, MEK and ERK. Activated ERK can 
translocate into the nucleus, where it catalyses the phosphorylation of transcription 
factors such as p62TCF, initiating a transcriptional programme that leads to 
cellular proliferation or differentiation (Boulton et al. 1991). 
 
 
 
Figure 3: Signal transduction in insulin action. The insulin receptor is a tyrosine kinase that 
undergoes autophosphorylation, and catalyses the phosphorylation of cellular proteins such as 
members of the IRS family, Shc and Cbl. Upon tyrosine phosphorylation, these proteins interact 
with signaling molecules through their SH2 domains, resulting in a diverse series of signaling 
pathways, including activation of PI(3)K and downstream PtdIns(3,4,5)P3 dependent protein 
kinases, Ras and the MAP kinase cascade. These pathways act in a concerted fashion to coordinate 
the regulation of vesicle trafficking, protein synthesis, enzyme activation and inactivation, and gene 
expression, which results in the regulation of glucose, lipid and protein metabolism. 
 
 
In addition to the above mentioned metabolic insulin action exerted on its 
canonical target tissues (muscle, fat and liver), it has recently become evident that 
insulin also acts on endothelium where, through the activation of its own receptor, 
it regulates the vascular tone (Sherrer et al. 1994).  
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1.2 Endothelium. 
 
By the nature of its location, the endothelium acts as a blood container, but in 
addition, it actively regulates the passage of nutrients, hormones, and 
macromolecules into the surrounding tissue (Cersosimo and DeFronzo 2006). It  is 
covered by a glycocalyx that contributes to the selectivity of its barrier function 
(van Haaren et al. 2003). Furthermore, the endothelium ensures the fluidity of 
blood by its contribution to hemostasis. Indeed, living endothelial cells are needed 
to prevent and limit blood coagulation and the formation of a platelet thrombus 
and to produce fibrinolysis regulators (van Hinsbergh 2001). The interaction 
between flowing blood and endothelium not only involves the interaction of blood 
constituents and cells with the endothelium, but also includes the sensing of 
mechanical forces, in particular shear forces that are exerted by the flowing blood 
on the endothelium. This sensing enables the endothelial cell to respond by acute 
vasoregulation and by inducing chronic adaptation of the blood vessel. Acute 
vasoregulation is achieved by the production of vasodilator factors, such as nitric 
oxide (NO), endothelium derived hyperpolarization factor (EDHF), and 
prostaglandins (PGI2/PGE2), of which the relative contribution varies between the 
different types of vessels (Shimokawa et al. 1996). Furthermore, in specific 
conditions, the endothelium is also able to induce the potent vasoconstrictor 
endothelin-1 (ET-1). Insulin also acts as a regulator of vasoregulation, as it is able 
to induce NO and ET-1 release (Schroeder et al. 1999; Cardillo et al. 1999; Ferri et 
al. 1995). Through the production of these chemical mediators, the “endothelial 
system” exerts actions on the surrounding vascular smooth muscle cells (vSMC) 
and cells in the blood leading to: vasodilation  (bradykinin, NO) or 
vasoconstriction (ET-1, angiotensin II, radical oxygen species-ROS) of vSMC, 
stimulation of growth and changes in phenotypic characteristics of vSMC 
(angiotensin II, ROS) or inhibition of vSMC proliferation (NO), and manteinance 
of blood fluidity and normal coagulation (plasminogen activator inhibitor I) 
(Pandolfi and De Filippis 2007). Another important function of the endothelium 
lies in the regulation of a proper recruitment of leukocytes at sites of inflammation 
or an immune reaction. Again, both acute responses and chronic adaptation can 
cause induction of leukocyte adhesion molecules and other gene products. 
Inflammatory activation of the endothelium can occur, for example, after exposure 
to bacterial lipopolysaccaride and inflammatory cytokines, of which the potent 
inducers interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNFα) have drawn 
the most attention. Inflammatory activation can also be induced by reactive 
oxygen intermediates (ROIs), which can be generated by the inflammation process 
itself and by disturbed metabolic conditions (Gimbrone 1999). Finally, the 
endothelium is the major vector in angiogenesis, the formation of new 
microvessels. This is not only important in development, growth, and tissue repair, 
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but also in capillary perfusion of muscle. Furthermore, in a number of diseases, an 
improper angiogenesis response causes unwanted growth, risk for local 
haemorrhage by immature vessels, or insufficient blood supply (Carmeliet 2005).  
 
 
1.2.1 Insulin action on endothelium. 
 
As reported above, endothelium is a new target tissue of insulin action. Insulin 
acts on endothelium as a mediator of vasoregulation, inducing the release of the 
vasodilator NO and the vasoconstrictor ET-1 (Schroeder et al. 1999). Insulin 
binding to its receptor on the endothelial cells activates the insulin receptor 
substrates: IRS-1 and IRS-2, thereby activating two different branches of insulin 
signaling. On one side, phosphatidyl inositol 3-kinase(PI3K) complexes with the 
phosphorylated IRS-1, activates by phosphorylation PKB/Akt, that in turns 
phosphorylates endothelial nitric oxide synthase (eNOS) at Ser1177 inducing its 
dimerization, NO release, and thus, vasodilatation (Zeng et al. 2000). The eNOS 
dimer generates NO by means of the conversion of arginine in(to) NO and L-
cytrulline by a ratio of 1 to 1. This is an oxygen and NADPH-dependent reaction.  
Once produced, NO acts on vSMCs inducing their relaxation through the 
inhibition of the contractile apparatus and the activation of the cytosolic guanilate 
cyclase (cGC), leading to the increase of cyclic guanosine monophosphate 
(cGMP) intracellular levels (Andreozzi et al. 2007).  
On the other side, through the activation of IRS-2, insulin activates the pro-
atherogenic Ras-Raf-MAPK pathway which is associated with gene expression, 
mitogenesis, cell growth and, in the vascular endothelial cells, the activation of 
endothelin converting enzyme-1 (ECE-1) that produces the vasoconstrictor ET-1. 
Most of ET-1 is released at the abluminal side, where acts on vSMC inducing their 
contraction and proliferation, in addition to its chemotactic action to circulating 
monocyte (Cardillo et al. 1999; Kubota et al. 2003; Montagnani et al. 2002).  
Defective insulin signalling causes reduced eNOS expression, inadequate 
production of NO and ET-1 and endothelial dysfunction both in vitro and in vivo 
(Bakker et al. 2009; Vincent et al. 2003; Federici et al. 2004). A selective 
impairment of the insulin-activated Akt signaling pathway with an intact MAPK 
pathway have been shown to underlie the profound insulin resistance in type 2 
diabetic and obese non-diabetic individuals (Cusi et al. 2000). Furthermore, 
vasodilatation in response to insulin is blunted in skeletal muscle arterioles from 
insulin resistant animals, due to altered NO release through the PI3K/eNOS 
pathway (Eringa et al. 2007). In arteries from type 2 diabetic patients, the Akt 
signaling pathway is also downregulated leading to a decreased NO availability 
and therefore compromising arterial function (Okon et al. 2005).   
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Figure 4: Insulin signal transduction in endothelial cells. 
 
 
1.3 Endothelial dysfunction.  
 
The functioning of the endothelium is flexible and adapts to various types of 
metabolic, mechanical, and inflammatory stress (Cines et al. 1998; Pober and 
Sessa 2007). However, when this functioning becomes inadequate, e.g., loss of 
NO generation, or exaggerated, e.g., improper inflammatory activation, one speaks 
of endothelial dysfunction. From a mechanistic point of view, as many endothelial 
dysfunctions exist as endothelial functions. They include changes in barrier 
function and hemostasis, reduced vasodilator responses, improper inflammatory 
activation, and angiogenesis (Table 1). In the clinical context, endothelial 
dysfunction is regarded as an important and early factor in the pathogenesis of 
atherothrombosis (Gimbrone 1999; Ross 1999) and vascular complications of 
diabetes (Stehouwer et al. 1997) and is associated with a number of traditional risk 
factors including hypercholesterolemia, smoking, hypertension, diabetes mellitus, 
insulin resistance and, more recently, obesity (Brook et al. 2001). 
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Table 1: Endothelial dysfunctions associated with the occurrence and severity of vascular 
complications in diabetes. 
 
 
In diabetes, the basement membrane is thickened and altered in composition, 
because of the enhanced synthesis of matrix proteins by transforming growth 
factor beta (TGF-β) activity (Chen et al. 2001). At the same time, the thickness of 
the glycocalyx, which contains large amounts of heparan sulfate proteoglycans, is 
markedly reduced (Nieuwdorp et al. 2006a, 2006b). Loss of the glycocalyx leads 
to the adhesion of mononuclear cells and platelets to the endothelial surface, 
attenuated NO availability, and to an increased leakage of macromolecules 
through the endothelium of many vessels in hyperglycemia and diabetes (Berg et 
al. 2006). Hyperglycemia is an etiological factor of endothelial barrier injury, as it 
can stimulate crosslinking and modification of matrix proteins by glyco-oxidation 
(Naka Y et al. 2004). 
A key feature of endothelial dysfunction is the reduced vasodilator response, that 
limits the delivery of nutrients and hormones to the distal tissues. Two 
mechanisms play an important role: the decreased bioavailability of the vasodilator 
NO, and the increased synthesis of ET-1 by activated endothelial cells inducing 
vasoconstriction. The bioavailability of NO is determined by a balance of NO 
production by eNOS and reduction of active NO by quenching of NO by ROIs. 
ROIs, and superoxide anion in particular, react with NO and form peroxynitrite 
that contributes to eNOS uncoupling, thus aggravating reduced NO production. 
Moreover, ROIs reduce the availability of tetrahydrobiopterin (BH4), a cofactor 
required for NO synthesis from eNOS, and inhibits the enzyme dimethylarginine 
dimethylaminohydrolase (DDAH) that converts the endogenous eNOS inhibitor 
16 
 
asymmetric dimethylarginine (ADMA), thus suppressing NO production (Lin et 
al. 2002). Insulin resistance and oxidative stress, such as that induced by 
hyperglycemia, can both contribute to an increased production of the potent 
vasoconstrictor ET-1. The balance between NO- and ET-1-dependent pathways 
plays a major role in vasoregulation by insulin and the dysfunction of 
vasoregulation in diabetes and obesity. Other vasodilating factors such as 
endothelium-derived hyperpolarization factor (EDHF) may also be altered in 
diabetic animals (De Vriese et al. 2000).  
The generation of ROIs and AGEs also activates the nuclear factor kappa-B (NF-
κB) pathway with, subsequently, the activation of numerous genes involved in 
inflammation, including  C reactive protein (CRP), PECAM-1, VCAM-1 and 
ICAM-1 (Pober and Sessa 2007). As they represent major receptors controlling the 
influx of monocytes and other inflammatory cells into the arterial wall, their 
expression is considered as a hallmark in the etiology of atherosclerosis 
(Gimbrone et al. 1999).  
Several proteins involved in hemostasis have been evaluated as potential risk 
indicators of cardiovascular disease in diabetes (Alessi and Juhan-Vague 2008). 
Among these: increased soluble thrombomodulin and  Von Willembrant Factor 
(vWF) levels may point to a procoagulant state; decreased plasminogen activator 
and increased PAI-1 levels may point to reduced fibrinolysis.  
Finally, the regeneration function of endothelial cells as represented by 
angiogenesis is dysfunctional in hyperglycemia and diabetes. Diabetes patients 
have poor wound healing, impaired collateral formation after vascular occlusion or 
myocardial infarction, and an increased risk of rejection of transplanted organs 
(Martin et al. 2003). Reduced vascularization probably also contributes to diabetic 
neuropathy. In contrast, an excessive neovascularization is observed in the eyes of 
patients with diabetic retinopathy, where hyperinsulinemia and overactivation of 
insulin and insulin-like growth factor-1 receptors  contribute to VEGF expression 
(Aiello 2005).  
 
 
1.4 Reciprocal relationships between endothelial dysfunction and 
insulin resistance. 
 
Many risk factors for CVD, including dyslipidemia, hypertension, diabetes, 
obesity, and physical inactivity enhance the risk of developing both endothelial 
dysfunction and insulin resistance. Thus, endothelial dysfunction and insulin 
resistance frequently co-exist (Muniyappa 2008). 
Recent studies report that higher levels of circulating plasma markers of 
endothelial dysfunction (PAI-1, vWF, E-selectin, ICAM-1) increase the risk of 
developing diabetes, supporting a potential causal role for endothelial dysfunction 
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in insulin resistance (Meigs et al. 2006). The central role of endothelium in 
regulating metabolic actions of insulin is also evident by the presence of insulin 
resistance and hypertension in eNOS knockout mice. In addition to microvascular 
changes including reduced capillary density, these animals show reduced glucose 
disposal, energy expenditure, increased triglyceride and FFA levels, and impaired 
mitochondrial function (Duplain et al. 2001). These studies prove that in animal 
models like in humans,  partial defects in endothelial function characterized by 
reduced NO bioavailability are sufficient to cause cardio-metabolic abnormalities 
(insulin resistance and dyslipidemia) under pathogenic conditions (e.g., caloric 
excess, physical inactivity, inflammation). 
On the other hand, in humans with metabolic insulin resistance (obese and type 2 
diabetic subjects) there is parallel impairment in insulin’s ability to induce 
vasodilation. At the cellular level, a key feature of insulin resistance is the 
pathway-selective impairment in PI3K-dependent signaling pathways while other 
insulin signaling branches including Ras/MAPK-dependent pathways are 
relatively unaffected. This has important pathophysiological implications because 
metabolic insulin resistance is typically accompanied by compensatory 
hyperinsulinemia to maintain euglycemia. In the vasculature and elsewhere, 
hyperinsulinemia will overdrive unaffected MAPK-dependent pathways leading to 
an imbalance between PI3K- and MAPK-dependent of insulin functions.  The 
imbalance between PI3K/Akt/eNOS/NO and MAPK/ET-1 vascular actions of 
insulin provoked by dyslipidemia, hyperglycemia, and inflammatory cytokines 
may contribute to both impaired vascular and metabolic insulin actions. Indeed, 
compensatory hyperinsulinemia that typically accompanies pathway selective 
insulin resistance (in PI3K pathways) activates unopposed MAPK pathways 
leading to enhanced pro-hypertensive and atherogenic actions of insulin (Kim et 
al. 2006). 
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Figure 5: Relationship between insulin resistance and endothelial dysfunction. Parallel  
PI3k–dependent insulin-signaling pathways in metabolic and  vascular tissues synergistically 
couple metabolic and vascular physiology under healthy conditions (on the left). Parallel 
impairment in insulin-signaling pathways under pathological conditions contributes to synergistic 
coupling of insulin resistance and endothelial dysfunction (on the right). 
 
 
1.4.1 Potential mechanisms. 
 
Shared causal factors such as glucotoxicity, lipotoxicity, inflammation, and 
oxidative stress interact at multiple levels to create reciprocal relationships 
between insulin resistance and endothelial dysfunction that may help to explain the 
frequent clustering of metabolic and cardiovascular disorders.  
 
Proinflammatory Cytokines 
Insulin resistance and endothelial dysfunction are characterized by elevated 
circulating markers of inflammation (Kim et al. 2006). Visceral fat accumulation 
may play a key role in the development of the systemic pro-inflammatory state 
associated with insulin resistance (Hotamisligil  2006). Among these cytokines, 
TNF-α activates a variety of serine kinases including JNK and IKKβ that directly 
or indirectly increase serine phosphorylation of IRS-1/2, leading to decreased 
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insulin-stimulated activation of PI3K/Akt/eNOS in endothelial cells (Gustafson et 
al. 2007; Anderson et al. 2004; Eringa 2004; Zhang et al. 2003). In addition, TNF-
α increases ET-1 secretion in a MAPK-dependent fashion (Sury 2006). Similarly, 
C-reactive protein (CRP) has important biological actions to inhibit insulin-evoked 
NO production in endothelial cells through specific inactivation of the 
PI3K/Akt/eNOS pathway, and increases endothelial ET-1 production. IL-6 also 
inhibits insulin-stimulated increases in eNOS activity and NO production in the 
endothelium (Andreozzi et al. 2007). Systemic infusion of high doses of TNF-α 
results in the loss of insulin-induced increases in glucose uptake, limb blood flow, 
and capillary recruitment in rat hind limb (Zhang et al. 2003). Thus, 
proinflammatory cytokines may contribute to coupling metabolic and vascular 
insulin resistance manifested by impaired insulin signaling and endothelial 
dysfunction. 
 
Adipokines 
Adipocyte-derived hormones such as leptin and adiponectin have both metabolic 
and vascular actions. Adiponectin is an anti-inflammatory peptide whose 
circulating levels are positively correlated with insulin sensitivity and that may 
serve to link obesity with insulin resistance (Koh et al. 2005). Similar to insulin, 
adiponectin has vasodilator actions as it stimulates NO production, enhances NO 
bioavailability by upregulating eNOS expression and reducing ROS production in 
endothelial cells (Motoshima et al. 2004). Decreased plasma adiponectin levels are 
observed in patients with obesity, type 2 diabetes, hypertension, metabolic 
syndrome, and CVD (Lau et al. 2005). Leptin is a key regulator of appetite, body 
weight and energy balance in the CNS and acts directly on the vasculature, where 
it induces endothelium-dependent vasodilation through a PI3K/Akt/eNOS pathway 
(Vecchione et al. 2002). Leptin evoked vasodilation is opposed by 
sympathetically-induced vasoconstriction.  In contrast to its vasodilator effects, 
leptin also increases sympathetic nerve activity. Paradoxically, circulating leptin 
levels are elevated in obesity, apparently contradicting the beneficial effects of 
leptin. To explain this, recent studies have demonstrated the impairment of leptin’s 
metabolic effects and leptin-induced NO production, i.e. “leptin resistance”, in 
obesity and human hypertension. Therefore, resistance to the vasodilator effects of 
leptin may contribute to vascular dysfunction in obesity (Bakker et al. 2008).  
 
Lipotoxicity 
Patients with type 2 diabetes mellitus or metabolic syndrome have a distinctive 
dyslipidemia characterized by hypertriglyceridemia, elevated blood levels of 
apolipoprotein B, small, dense LDL cholesterol, and low levels of HDL 
cholesterol. This contributes to endothelial dysfunction, atherosclerosis, and 
insulin resistance. Treatment of vascular endothelial cells with FFA impairs 
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insulin-stimulated activation of PI3K, PDK1, Akt and eNOS. Elevated cellular 
levels of lipid metabolites such as diacylglycerols, ceramide, and long-chain fatty 
acyl CoAs activate serine kinases such as PKC and IKKβ that cause insulin 
resistance by increasing serine phosphorylation of IRS-1 (Du et al. 2006; Kim et 
al. 2005; Wang et al. 2006). In support of these findings, raising circulating FFA 
levels significantly impairs insulin induced increases in skeletal muscle capillary 
recruitment with a concomitant decrease in glucose disposal (Clerk 2002). 
Moreover, FFA infusion in humans accentuates insulin-mediated ET-1 release. 
These studies suggest that in the context of pathway selective impairment of PI3K 
signaling induced by elevated FFA levels, insulin stimulates increased ET-1 
secretion through an unopposed MAPK signaling that leads to relative 
vasoconstriction and insulin resistance. 
 
Glucotoxicity 
Hyperglycemia associated with impaired glucose tolerance and diabetes causes 
insulin resistance and endothelial dysfunction by increasing oxidative stress, 
formation of advanced glycation end products (AGEs), and flux through the 
hexosamine biosynthetic pathway. Hyperglycaemia impairs insulin action in 
skeletal and cardiac muscle as well as in vascular endothelium. Activity of Akt and 
eNOS in vasculature and muscle is significantly attenuated in patients with 
diabetes when compared with non-diabetics (Kashyap et al. 2005. By contrast with 
deleterious effects on the PI3K/Akt/eNOS pathway, hyperglycemia enhances 
endothelial ET-1 secretion and thereby alters the balance between NO and ET-1 to 
favor vasoconstriction and endothelial dysfunction. An oral glucose load 
significantly increases plasma ET-1, in insulin-resistant, but not in healthy 
individuals (Desideri et al. 1997). Thus, a parallel increase in ET-1 activity and 
diminished NO bioactivity associated with hyperglycemia and insulin resistance 
may contribute to abnormal vascular function. This illustrates the altered balance 
between the vasodilator and vasoconstrictor actions of insulin in insulin resistant 
states that contributes to reciprocal relationships between insulin resistance and 
endothelial dysfunction (Muniyappa et al. 2008). 
 
 
1.5 Mechanisms of Glucotoxicity. 
 
Four main molecular mechanisms have been implicated in glucose-mediated 
vascular damage. These include: increased polyol pathway flux; activation of 
protein kinase C (PKC) isoforms; increased hexosamine pathway flux; and 
increased advanced glycation end-product (AGE) formation. All seem to reflect a 
single hyperglycaemia-induced process of overproduction of superoxide by the 
mitochondrial electron-transport chain (Brownlee 2001).  
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Figure 6: Potential mechanism by which hyperglycaemia -induced mitochondrial 
superoxide overproduction activates four pathways of hyperglycaemic damage. 
 
 
The first mechanism includes the aldose reductase activity. It’s the first enzyme 
in the polyol pathway, that catalyses the NADPH-dependent reduction of a wide 
variety of carbonyl compounds, including glucose. Aldose reductase has a low 
affinity for glucose, and at the normal glucose concentrations, metabolism of 
glucose by this pathway is a very small percentage of total glucose use. But in a 
hyperglycaemic environment, increased intracellular glucose results in its 
increased enzymatic conversion to the polyalcohol sorbitol, with concomitant 
decreases in NADPH. In the polyol pathway, sorbitol is oxidized to fructose by the 
enzyme sorbitol dehydrogenase, with NAD+ reduced to NADH. The mechanisms 
proposed to explain the potential detrimental effects of hyperglycaemia-induced 
increases in polyol pathway flux, include sorbitol-induced osmotic stress, 
decreased (Na++K+)ATPase activity, an increase in cytosolic NADH/NAD+ and a 
decrease in cytosolic NADPH. Sorbitol does not diffuse easily across cell 
membranes, and it was originally suggested that this resulted in osmotic damage to 
microvascular cells. It has also been proposed that reduction of glucose to sorbitol 
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by NADPH consumes NADPH. As NADPH is required for regenerating reduced 
glutathione (GSH), this could induce or exacerbate intracellular oxidative stress.  
The PKC family comprises at least eleven isoforms, nine of which are activated 
by the lipid second messenger diacylglycerol (DAG), that is increased by 
intracellular hyperglycaemia in cultured microvascular cells and in the retina and 
renal glomeruli of diabetic animals. Hyperglycaemia seems to achieve this 
primarily by increasing de novo DAG synthesis from the glycolytic intermediate 
dihydroxyacetone phosphate, through reduction of the latter to glycerol-3-
phosphate and stepwise acylation (Koya and King 1998). Besides, it may also 
activate PKC isoforms indirectly through both ligation of AGE receptors (Portilla 
et al. 2000) and increased activity of the polyol pathway (Keogh et al. 1997), 
presumably by increasing reactive oxygen species. The activation of PKC-β and 
PKC-δ has been shown to mediate blood flow abnormalities by depressing nitric 
oxide production and/or increasing endothelin-1 activity (Fig. 3), inhibiting the 
insulin-stimulated expression of eNOS mRNA (Kuboki et al. 2000), increasing 
ET1-stimulated MAPK activity, and inducing the expression of the permeability 
enhancing factor VEGF in smooth muscle cells (Williams et al.  1997). Moreover, 
activation of PKC contributes to increased microvascular matrix protein 
accumulation by inducing expression of TGF-β1, fibronectin and type IV collagen 
both in cultured mesangial cells and in glomeruli of diabetic rats (Koya et al. 
1997). Hyperglycaemia-induced activation of PKC has also been implicated in the 
overexpression of the fibrinolytic inhibitor PAI-1, the activation of NF-kB and of 
various NAD(P)H-dependent oxidases, leading to a pro-inflammatory state 
(Yerneni et al. 1999) and the increase of ROS formation.   
Shunting of excess of intracellular glucose into the hexosamine pathway might 
also cause several manifestations of diabetic complications (Kolm-Litty et al. 
1998). (Fig. 4). In the physiological state, about 1-3% of intracellular glucose is 
diverted from glycolysis to this pathway, through which fructose-6-phosphate is 
converted to N-acetylglucosamine by fructose-6-phosphate amidotransferase 
(GFAT). Next, N-acetylglucosamine is transformed to N-acetylglucosamine 1-6 
bisphosphate, and then, to UDP-N-acetylglucosamine, the allosteric inhibitor of 
GFAT and substrate of O-GlcNAc transferase (OGT), which catalyzes the binding 
of N-acetylglucosamine to serine and threonine residues through the O-
glycosylation of various proteins. Among these, it has been demonstrated that the 
covalent modification of the transcription factor Sp1 by N-GlcNAc makes this 
factor more transcriptionally active, explaining the hyperglycaemia-induced 
increase of PAI-1 activation. In addition to transcription factors, another example 
of O-linked GlcNAc protein modification  relevant to diabetic complications is the 
inhibition of eNOS activity by hyperglycaemia-induced O-
acetylglucosaminylation at the Akt site of the eNOS protein (Du et al. 2001). 
Studies performed in our laboratory have demonstrated that high levels of GlcN, 
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similar to those found in diabetic patients, cause insulin-resistance in both human 
and rat myotubes through the induction of ER Stress. Moreover, GlcN-induced ER 
stress impairs GLUT4 production and insulin-induced glucose uptake via an 
ATF6-dependent decrease of the GLUT4 regulators MEF2A and PGC1α 
(Iadicicco et al. 2010). Furthermore, we have also found that GlcN-induced ER 
Stress causes de-differentiation of β-cells both in INS-1E cells and in primary 
mouse islets. This is shown by the down-regulation of beta cell markers and of the 
transcription factor, pancreatic and duodenal homeobox 1 (figure 7a-d). The de-
differentiation of β-cells is associated to the loss of their physiological function as 
demonstrated by the inhibition of glucose-stimulated insulin-secretion in figure 7.e 
(Lombardi et al. 2011).  
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Figure 7: Effects of GlcN on beta cell-associated gene expression and glucose-induced 
insulin secretion in INS-1E cells. 
25 
 
Thus, activation of the hexosamine pathway by hyperglycaemia may result in 
many changes in both gene expression and protein function, which together 
contribute to the pathogenesis of diabetic complications. 
AGEs are a heterogeneous family of irreversible non-enzymatically glycated 
molecules. AGEs form by the Maillard process, a non-enzymatic reaction between 
ketones or aldehydes and the amino groups of proteins, nucleic acids and lipids, 
contributing to the aging of these molecules and to the pathological complications 
of diabetes. In high glucose conditions, glucose reacts non-enzymatically with the 
amino groups of proteins to form a Shiff base, by means of a reversible protein 
glycosilation. If hyperglycemia persists, a Shiff base can rearrange to form a 
ketoamine adduct, so-called Amadori product, as a more stable glycated product. 
Finally, these early products eventually undergo further “irreversible” chemical 
modifications generating different classes of advanced glycation end products. 
Recent studies have suggested that AGEs can arise not only directly from sugars, 
but also from carbonyl compounds derived from the autoxidation of sugar 
(i.e.:glyoxal) and the fragmentation of the intermediate products or de-
phosphorylation of triose phosphates, like MGO. These are highly reactive 
dicarbonyls, which can react with lysine and arginine functional groups on 
proteins, leading to the formation of stable AGE compounds, such as N-
(carboxymethyl)lysine (CML) and  N-(carboxyethyl)lysine (CEL) (Yamagishi and 
Takeuchi 2004). 
  
 
Figure 8: Alternative routes for the formation of AGEs. 
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AGEs are prevalent in the diabetic vasculature and contribute to the development 
of atherosclerosis. The presence and accumulation of AGEs in many different cell 
types affect extracellular and intracellular structure and function. AGEs contribute 
to a variety of microvascular and macrovascular diabetic  complications through 
the formation of cross-links between molecules in the basement membrane of the 
extracellular matrix and by engaging the receptor for advanced glycation end 
products (RAGE). Activation of RAGE by AGEs causes upregulation of the 
transcription factor nuclear factor-kβ and its target genes. AGE-bound RAGE 
increases endothelial permeability to macromolecules. AGEs block nitric oxide 
activity in the endothelium and cause the production of reactive oxygen species. In 
the ECM, AGEs form on a variety of different molecules, including lipids, 
collagen, laminin, elastin, and vitronectin. The formation of AGEs on ECM 
molecules alters the constitution of the matrix and increases stiffness. AGEs also 
activate the transforming growth factor (TGF)-receptor to stimulate cell growth, 
leading to increased ECM production. AGEs that bind to RAGE on the endothelial 
cell surface lead to a signaling cascade, stimulating NAD(P)H oxidase and 
increasing ROS, p21 RAS, and MAPKs. In addition, the ligand-RAGE interaction 
also may stimulate signaling via p38 MAPK and Rac/Cdc. A key target of RAGE 
signaling is NF-kB. NF-kB is translocated to the nucleus, where it increases 
transcription of a number of different proteins, including endothelin-1, ICAM-1, 
E-selectin, and tissue factor. AGE and ligands for RAGE, such as HMGB1 and 
S100 calgranulins, trigger inflammatory pathways. Moreover, AGE may decrease 
NO availability by the decreased activity of NOS and by quenching NO. Then, 
AGEs activate monocytes, causing increased expression of macrophage scavenger 
receptor (MSR) class A receptors and CD36 receptors, leading to increased 
OxLDL uptake and foam cell formation, as represented in  figure 9 (Goldin et al. 
2006).  
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Figure 9: The extracellular and intracellular effects of AGEs. 
 
 
Besides the vasculature, the accumulation of AGEs that occurs in a 
hyperglycaemic environment also affects the insulin sensitivity of skeletal muscle. 
Indeed, as we have recently shown, in both L6 myotubes and in mice fed a high 
AGEs diet human glycated albumin (HGA) induces insulin resistance by 
activating protein kinase C α(PKCα), through the formation of a multimolecular 
complex including RAGE/IRS-1/Src and PKCα (Miele et al. 2003; Cassese et al. 
2008).    
Finally, it has recently become clear that AGEs also influence physiological 
aging and neurodegenerative diseases (Schlotter et al. 2009; Bierhaus and Nawroth 
2009).  
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1.6 Methylglyoxal.  
 
One of the main precursors of AGEs is Methylglyoxal (MGO). It belongs to a 
class of reactive carbonyl species known as the α-oxoaldehydes. These molecules 
contain 2 adjacent carbonyl groups and are therefore referred to as dicarbonyls . 
This chemical moiety makes the dicarbonyls a highly reactive class of carbonyl 
species, generated from carbohydrate metabolism and autoxidation, collectively 
referred to as ‘glycation’(Fleming et al. 2010). MGO is formed mainly by the 
fragmentation of Amadori products or the spontaneous degradation of 
triosephosphates (glyceraldehyde-3-phosphate and dihydroxyacetone phosphate) 
and also by the metabolism of ketone bodies, threonine degradation and the 
fragmentation of glycated proteins. Recent estimates for the concentration of 
MGO in human blood plasma are in the range of 100–120 nM, while cellular 
concentrations for MGO are in the range of 1–5 µM (Thornalley 2008). MGO 
serum concentration increases by 5-6 fold in patients affected by T1D, and by 2-3 
fold in T2D patients (McLellan et al. 2002). As the formation of dicarbonyls is 
closely linked to the rate of glycolysis within the cell and the presence of 
glycolytic intermediates, it would be expected that under conditions where there is 
either an increase in glycolytic flux or an increased dependence on glycolysis for 
energy, the rate of dicarbonyls formation will be increased. This has been shown 
to be the case in patients with diabetes mellitus, where complications such as 
nephropathy, neuropathy and retinopathy can be linked to increases in cellular 
levels of AGEs (Beisswenger et al. 2003). 
MGO is a potent glycating agents. As described above, glycation of proteins is a 
complex series of parallel and sequential reactions, that occur in all tissues and 
body fluids. Historically, the reactions of lysyl side chain and N-terminal amino 
groups with glucose to form fructosyl-lysine and fructosamines, respectively, have 
been the major glycation processes studied. The formation of these adducts under 
physiological conditions is now generally classified as an early glycation process. 
Later-stage reactions form stable end-stage adducts, the AGEs. Important AGEs 
quantitatively are hydroimidazolones derived from arginine residues modified by 
MGO. There is also concurrent formation of minor lysine derived adducts Nε-
carboxymethyl-lysine (CML) and Nε-carboxyethyl-lysine (CEL) residues, and 
bis(lysyl) crosslinks (GOLD and MOLD). DNA is susceptible to glycation by 
MGO too. The nucleotide most reactive under physiological conditions is 
deoxyguanosine (dG). The presence of nucleotide dG-MGO in DNA is associated 
with increased mutation frequency, DNA strand breaks and cytotoxicity 
(Thornalley 2008). 
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Figure 10: Non-enzymatic reactions leading to MGO formation. MGO derives from triose-
phosphates dephosphorylation, from lipid peroxidation and from threonine catabolism.  
 
 
1.6.1 Damaging effects of Methylglyoxal. 
 
The physiological importance of protein glycation is under intensive 
investigation. Particularly damaging effects are produced by covalent crosslinking 
of proteins which confers resistance to proteolysis. Protein modification is also 
damaging when amino acid residues are located in sites of protein-protein 
interaction, enzyme-substrate interaction and protein-DNA interaction (for 
transcription factors) (Fleming et al.  2010). The interaction of MGO with amino 
acids can induce oxidative stress and free radical production, involved in the 
pathogenesis of chronic diabetic complications, included retinopathy, nephropathy, 
and neuropathy. Moreover, MGO can increase oxidative stress trough the 
glycosylation and inactivation of antioxidant enzymes (i.e., glutathione reductase 
and glutathione peroxidase) (Kim et al. 2008). A bioinformatics analysis of 
receptor binding domains indicated that arginine residues have the highest 
probability of being located in such sites (19.6%) (Gallet et al. 2000). The major 
modification of proteins by MGO is on arginine residues. Formation of 
hydroimidazolones causes structural distortion, loss of side chain charge and 
functional impairment. Studies looking at the modification of human serum 
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albumin and vascular basement membrane type IV collagen by MGO have shown 
that formation of the hydroimidazolone causes loss of albumin  electrostatic 
interaction due to the disruption of arginine-directed hydrogen bonding (Ahmed et 
al. 2005), and endothelial cell detachment, anoikis and inhibition of angiogenesis 
because of the formation of hydroimidazolone residues at hotspot modification 
sites in integrin-binding sites of collagen (Dobler D et al. 2006).  
The oxidative damage induced by MGO-amino acids interaction leads to 
cytotoxicity and apoptosis as well. Indeed, it has been demonstrated that high 
levels of MGO can cause the apoptosis of bovine retina’s pericytes through the 
activation of the transcriptional factor NF-kβ; and treatment of pericytes with anti-
inflammatory agents inhibits the cytotoxicity induced by NF-kβ in response to 
MGO (Kim et al 2004). How MGO triggers apoptosis is not clear yet. Probably, 
Jun N-terminal Kinase (JNK) is activated by MGO and induces the cytochrome C 
release from mitochondria leading to mitochondrial dysfunction, oxidative stress, 
and then, cell death (Takagi et al. 2004).    
Furthermore, direct effects of MGO on lifespan have been demonstrated in the 
model organism C. elegans, in which increased detoxification of MGO by 
overexpression of its detoxifying enzyme Glyoxalase I (GLOI) increased lifespan 
by 40%, while RNAi-mediated silencing of GLO-I decreased lifespan by 40%. 
Overexpression of GLO-I also decreased dicarbonyl-derived AGEs as well as the 
concentration of markers of oxidative and nitrosative damage (Morcos et al. 2008; 
Schlotter et al. 2009).  
The association between high levels of MGO and insulin-resistance have been 
documented by several studies. Fructose-fed rats show serum accumulation of 
MGO together with increased triglycerides and insulin levels, hypertension and 
decreased insulin-stimulated glucose uptake in adipose tissue (Jia and Wu 2007). 
Also 3T3L-1 adipocytes treated with MGO show a reduced insulin signal 
transduction: the decreased phosphorylation of IRS-1, the reduced PI3K activity 
and glucose uptake in response to insulin stimulation. Moreover, MGO treatment 
of L6 skeletal muscle cells reduces the insulin dependent activation of 
IRS1/PI3K/Akt signaling activation and glucose uptake, independently of the 
formation of intracellular reactive oxygen species (Riboulet-Chavey et al. 2006). 
As demonstrated by our recent studies, also β-cell function is impaired by  MGO, which 
inhibits insulin-induced IRS/PI3K/PKB pathway activation, abolishes glucose-
indiced insulin secretion and the insulin- and glucose-induced expression of Ins1, 
Gck and Pdx1 mRNA in INS-1E cells (F. Fiory et al. 2011).  
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1.6.2 Detoxification of methyglyoxal:  the Glyoxalase system. 
 
Present in the cytosol of all cells, the glyoxalase system catalyses the conversion 
of reactive, acyclic α-oxoaldehydes into the corresponding α-hydroxyacids. It is 
composed of two enzymes, glyoxalase I and glyoxalase II, and a catalytic amount 
of GSH. Glyoxalase I catalyses the isomerization of the hemithioacetal, formed 
spontaneously from α-oxoaldehyde (RCOCHO) and GSH, into S-2-
hydroxyacylglutathione derivatives [RCH(OH)CO-SG]: 
RCOCHO + GSH ↔ RCOCH(OH)-SG 
→ RCH(OH)CO-SG 
Glyoxalase II catalyses the conversion of  S-2-hydroxyacylglutathione 
derivatives into α-hydroxyacids and re-forms GSH consumed in the glyoxalase I-
catalysed reaction step. The major physiological substrate for glyoxalase I is 
MGO, and this accumulates markedly when glyoxalase I is inhibited in situ by 
cell-permeable glyoxalase I inhibitors and by depletion of GSH. Other substrates 
are glyoxal (formed by lipid peroxidation and the fragmentation of glycated 
proteins), hydroypyruvaldehyde (HOCH2COCHO) and 4,5-doxovalerate (H-
COCOCH2CH2CO2H). Glyoxalase I activity prevents the accumulation of these 
reactive α-oxoaldehydes and thereby suppresses α-oxoaldehyde-mediated 
glycation reactions. It is, therefore, a key enzyme of the antiglycation defence. 
 
 
 
Figure 11: The glyoxalase system.  
 
Glyoxalase I activity is present in all human tissues. Specific activities of fetal 
tissues are approximatively 3 times higher than those of corresponding adult 
tissues. Human glyoxalase I is a dimer, expressed at a diallelic genetic locus, GLO, 
which encodes two similar subunits in heterozygotes; the three alloenzymes are 
designated GLO 1-1, GLO 1-2 and GLO 2-2. All alloenzymes have molecular 
mass of 46 kDa (Thornalley 2003).  
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The active site is situated in the dimer interface, with the inhibitor and essential 
Zn2+ ion interacting with side chains from both subunits. The zinc binding site 
(human isoform) comprises two structurally equivalent residues from each domain 
– Gln-33A, Glu-99A, His-126B, Glu-172B and two water molecules in octahedral 
co-ordination. S-Glycolylglutathione, S-D-lactoylglutathione and S-L-
glyceroylglutathione are formed from glyoxal, MGO and hydroypyruvaldehyde 
respectively by glyoxalase I, and hydrolysed to glycolate, D-lactate and L-
glycerate respectively by glyoxalase II (Clelland and Thornalley 1991). 
The suppression of α-oxoaldehyde-mediated glycation by glyoxalase I is 
particularly important in diabetes and uraemia, where α-oxoaldehyde 
concentrations are increased. Convincing experimental evidence that glyoxalase I 
suppresses the formation of AGEs came from studies of endothelial cells in 
normoglycaemic and hyperglycaemic culture. Hyperglycaemia induced increases 
in the concentrations of MGO, D-lactate and AGEs. Overexpression of glyoxalase 
I prevented totally the increase in MGO and cellular protein AGEs, and increased 
the concentration of D-lactate (Shinohara et al. 1998). Furthermore, Glo-I 
overexpression in diabetic rats reduced hyperglycaemia-induced levels of carbonyl 
stress, AGEs, and oxidative stress (Brouwers et al. 2011). This indicated that 
glyoxalase I has a critical role in suppressing the formation of protein AGEs. The 
activity of glyoxalase I is proportional to the cellular concentration of GSH. 
Indeed, experimental depletion of GSH, by oxidative or non-oxidative 
mechanisms, induced marked accumulation of MGO and much smaller increase in 
glyoxal, and induced cytotoxicity (Abordo et al. 1999). The cytotoxicity associated 
with the accumulation of MGO and other glyoxalase I substrates should be 
avoided under normal physiological states. Hence the function of glyoxalase I is 
the detoxification of α-oxoaldehydes as part of the enzymatic defence against 
glycation. In certain disease states, such as cancer and microbial infections, one 
may wish to induce cytotoxicity of tumour cells and microbial organisms 
pharmacologically. A cell-permeable glyoxalase I inhibitor achieves this. 
SpBrBzGSH (S-p-bromobenzylglutathione) is a potent inhibitor of human 
glyoxalase I. Diesterification of SpBrBzGSH stabilizes this GSH conjugate to 
extracellular degradation by γ-glutamyl transpeptidase and makes it cell 
permeable. Inside cells, SpBrBzGSH diesters are de-esterified and glyoxalase I is 
inhibited. SpBrBzGSHCp2 (SpBrBzGSH cyclopentyl diester) is a potent 
antitumour agent in vitro and has antitumour activity in vivo (Thornalley et al. 
1996). Surprisingly, more recent studies have shown overexpression of glyoxalase 
I associated with multidrug resistance in cancer chemotherapy, where potent 
antitumuoral activity was achieved with SpBrBzGSHCp2, suggesting a role of 
MGO-induced apoptosis in the mechanism of action of some antitumour drugs 
(Thornalley 2003).  
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AIMS OF THE STUDY 
 
 
Diabetes Mellitus is an important risk factor for the development of micro- and 
macro-vascular disease. As a result, diabetic subjects  have a much higher risk 
than healthy subjects of developing atherosclerosis, nephropathy and heart attack. 
Endothelial dysfunction plays a pivotal role in the onset and progression of 
diabetic vascular complication. Several metabolic disorders cause endothelial 
damage, by modifying the balance between NO production and its inactivation. In 
particular, insulin-resistance, characteristic of type 2 diabetes, plays a key role in 
the development of endothelial dysfunction. Indeed, in addition to its classical 
hypoglycaemic function, insulin also acts as a vaso-regulatory hormone. Although 
the mechanism by which insulin action is altered in the endothelium of diabetic 
subjects is still unclear, it’s known that chronic hyperglycaemia is involved in the 
onset of insulin-resistance and in the progression of diabetic vascular 
complications. The aim of this study is to investigate the effects of methylglyoxal, 
one of the main products of chronic hyperglycaemia, on the insulin sensitivity of 
endothelium and on endothelial function both in vitro and in vivo, in order to 
identify the molecular mechanism/s by which this reactive metabolite may alter 
the vascular functions.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
MATERIALS AND METHODS 
 
 
Reagents. Media, sera and antibiotics for cell culture were from Lonza 
(Walkersville, MD, USA). Protein electrophoresis and western blot reagents were 
from Bio-Rad (Richmond, VA, USA) and ECL reagents from Pierce (Rockford, 
USA). Protein-A sepharose and MGO (40% in water solution) were from Sigma 
(St Louis, MO, USA). Insulin was from Eli Lilly (FI, Italy). The antibodies used 
were anti-phospho-TyrIRS-1 (Millipore, Billerica, MA, USA ), anti-IRS-1, anti-
p85, anti-GSK-3β,  (Upstate biotechnology, Lake Placid, NY), anti-Akt, anti-
phospho-Ser473Akt, anti-phospho-Ser21GSK3β, anti-eNOS, anti-phospho-
Ser1177eNOS, anti-phospho-Thr497eNOS (Cell Signaling Technology, Inc. 
Beverly, MA), anti-ERK1/2, anti-phospho-ERK1/2 (Santa Cruz, CA, USA). 
U0126 were from ENZO Lifescience (FI, Italy). The inhibitor of glyoxalase 1 
(SpBrBzGSHCp2) was kindly provided by A. Bierhaus (University of Heidelberg, 
Heidelberg, Germany). All other chemicals were from Sigma (St Louis, MO, 
USA). 
 
Cell culture procedure. Bovine aortic endothelial cells were plated in T75 flask 
and grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 1 g/liter 
glucose supplemented with 10% (v/v) fetal bovine serum and 2mM glutamine. 
Cultures were maintained at 37 °C in a humidified atmosphere containing 5% 
(v/v) CO2. Cells were starved in serum-free medium containing 0.2% (wt/vol.) 
BSA, pretreated or not with MGO 500 μM for the appropriated times, and then 
exposed or not to 100 nmol/l insulin. Where indicated, cells were pretreated for 30 
minutes with U0126 15 μM, or 48 hours with 10 μM SpBrBzGSHCp2. 
 
Western Blot analysis. For Western blot analysis, cells were solubilized in lysis 
buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM EDTA, 10 mM Na2P2O7, 
2 mM Na3VO4, 100 mM NaF, 10% glycerol, 1% Triton X-100, 1 mM 
phenylmethylsulfonylfluoride, 10 μg/ml aprotinin) for 2 h at 4°C. Cell lysates 
were clarified by centrifugation at 13000 rpm for 20 min. To analyze the 
phosphorylation of IRS-1 and its interaction with p85, 250 μg of protein lysates 
were incubated with IRS-1 antibodies and then precipitated with protein A-
Sepharose. Cell lysates or immunoprecipitated proteins were then separated by 
SDS-PAGE and transferred into 0.45-μm Immobilon-P membranes (Millipore, 
Bedford, MA). Upon incubation with primary and secondary antibodies, 
immmunoreactive bands were detected by ECL according to the manufacturer's 
instructions. 
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Measurement of NO. NO measurement was performed on cell culture medium 
or on mice serum. For the in vitro experiments, after treatments, culture medium 
was collected, centrifuged at 1000xg for 15 minutes, and the supernatant used as a 
sample solution for the detection. Serum was collected from the animals after 
cervical dislocation, treated with Centricon 10 (Amicon, Beverly, MA) at 7500 
rpm for 1 hour at 4 °C to remove haemoglobin and proteins. NO concentration was 
detected by the use of Nitrate/nitrite Assay Kit Colorimetric (Sigma-Aldrich 
Chemie GmbH, Switzerland). This assay uses the Griess reaction that forms a 
chomophoric azo-derivatives which absorbs light at 540-570 nm.  
 
Animals and MG administration. 4-Week-old C57/BL6 female mice (n. 30) 
were purchased from the Charles River Laboratories (Milan, Italy). Animals were 
kept under a 12-h light/12-h dark cycle, and all experimental procedures and 
euthanasia described below were approved by Institutional Animal Care and 
Utilization Committee. MG was administered intraperitoneally over 5 consecutive 
days each week for 7 consecutive weeks. The initial dose administered was 50 
mg/kg of body weight for the first 2 weeks, followed by a dose of 60 mg/kg of 
body weight for weeks 3 and 4, and finally a dose of 75 mg/kg of body weight for 
the last 3 weeks. Body weight was recorded weekly throughout the study. The 
animals were divided into 3 groups and injected with a 40% MGO solution (10 
mice), physiologic solution (10 mice), or not treated (10 mice).  After 7 weeks of 
treatment, animals from each group were sacrificed by cervical dislocation, the 
sera were collected, and the aortae isolated and homogenized as previously 
reported (Cassese et al. 2008).  
 
Insulin tolerance test. Mice were fasted for 4 hours followed by intraperitoneal 
(IP) insulin injection (0.75 IU/kg body weight). Whole venous blood was obtained 
from the tail vein at 0, 15, 30, 60, 90 and 120 min after the injection. Blood 
glucose was measured using an automatic gluco-meter (One Touch, Lifescan, 
Daly). 
 
Statistical procedures. Data were analysed with Statview software (Abacus-
concepts) by one-factor analysis of variance. p values of less than 0.05 were 
considered statistically significant. 
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RESULTS 
 
 
2.1 Effect of MGO on insulin signaling in endothelial cells in vitro. 
 
It has recently been demonstrated that MGO alters tyrosine phosphorylation of 
IRS-1 in response to insulin in L6 rat skeletal muscle cells (Riboulet-Chavey et al. 
2006). Aiming at analyze if this α-ketoaldehyde had the same effects in bovine 
aortic endothelial cells (BAEC), these cells were treated with or without 500 µM 
of MGO over 16 hours, and then, stimulated with 100 nM insulin for 10 minutes. 
Cells were lysated and 500 µg of proteins per sample were immunoprecipitated 
with anti-IRS-1 antibodies. The immunoprecipitates were processed by SDS-
PAGE and analyzed trough immunoblot by anti-phospho-tyrosine antibodies, in 
order to test the tyrosine-phosphorylation levels of the immunoprecipitated 
proteins. As shown in figure 12.a, 10 minutes of 100 nM insulin incubation 
induces a two-fold increase of IRS-1 tyrosine-phosphoylation in control cells. On 
the contrary, insulin is not able to induce any significant increase of IRS-1 
tyrosine-phosphorylation in BAEC treated with 500 µM MGO for 16 hours. This 
result suggests that MGO impairs insulin-dependent activation of IRS-1 in 
endothelial cells. 
It has previously been demonstrated that MGO exerts an inhibitory effect on PI3-
K activation and on the interaction of its regulatory subunit p85 with 
phosphorylated IRS-1 (Riboulet-Chavey et al. 2006). Hence, we tested whether 
MGO produced this effect also in endothelial cells. As shown in figure 12.b, 
insulin increases by 2.5-fold the interaction between PI3-K regulatory subunit p85 
and IRS-1 in control cells, whilst no interaction was observed after insulin 
stimulation in MGO-treated cells.               
To verify whether the inhibitory effect of MGO on IRS-1 tyrosine-
phosphorylation in response to insulin may lead to alterations in the signal 
transduction pathway downstream PI3-K, we checked the phosphorylation levels 
of Akt/PKB, a serine-kinase activated by PI3-K. As shown in figure 12.c, insulin 
induces a ~30% increase of Akt phosphorylation on serine 473 in control cells. By 
contrast, on serine 473 phosphorylation is not increased in response to insulin in 
cells treated with MGO for 16 hours. To confirm the MGO dependent inhibition of 
Akt activity in response to insulin, we tested the serine phosphorylation levels of 
the Akt substrate GSK3β. In figure 12.d is shown that 16 hours of MGO treatment 
inhibits the insulin-dependent serine phosphorylation of GSK3, confirming that 
MGO is able to impair insulin-induced Akt activity. 
Since in endothelial cells the activation of the IRS-1/PI3K/Akt pathway by 
insulin results in the production of the vasodilator nitric oxide mediated by eNOS, 
we analyzed the activation levels of this enzyme in BAEC treated with MGO. 
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eNOS can be phosphorylated by Akt on different residues producing opposite 
effects: the phosphorylation on serine 1177 induces a 15-20 fold increase of the 
enzymatic activity; the phosphorylation on threonine 497 induces the inhibition of 
the enzymatic activity (Andreozzi et al. 2007). Insulin stimulation causes a 2-fold 
reduction of threonine 497 phosphorylation levels in BAEC (figure 12.f) whilst, as 
expected, the phosphorylation on serine 1177 follows the opposite trend in these 
cells (figure 12.e). On the contrary, insulin is not able to reduce eNOS threonine 
497 phosphorylation in cells pretreated with MGO for 16 hours (figure 12.f), 
whereas the phosphorylation levels on serine 1177 are strongly reduced both in the 
presence and in the absence of insulin stimulation (figure 12.e). 
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Figure 12: MGO impairs the insulin-stimulated activation of IRS1/PI3K/Akt pathway in 
endothelial cells. Bovine aortic endothelial cells (BAEC) were treated with 500 µM MGO for 6 or 
16 hours and stimulated or not with 100 nM insulin for 10 minutes. Protein lysates obtained from 
these cells, by TAT1% treatment, were immunoprecipitated with anti-IRS-1 antibody and then 
analyzed by Western Blot with anti-p-tyrosine, anti-p85 and anti-IRS-1 antibodies as normalization 
of the protein content (a, b); or directly tested by Western Blot assay with anti-p-Akt, anti-Akt (c), 
anti-p-GSK3β, anti-GSK3β (d), anti-pSer1177-eNOS, anti-pThr495-eNOS, anti-eNOS (e, f), as 
indicated. To ensure accurate normalization, the same blots were probed with anti-14-3-3 antibody. 
The bars in the graphs represent the mean ± standard deviation of the values obtained by the 
densitometric analysis of at least three independent experiments. Statistical significance was 
evaluated using the Student’s t test. A value of p0.05 was considered statistically significant. 
 
 
In order to verify whether the inhibitory effect of MGO on eNOS activity would 
be followed by an impaired production of nitric oxide by endothelial cells, we 
measured nitric oxide content in the culture medium by means of a colorimetric 
assay. As shown in figure 13, the levels of nitric oxide into the culture medium of 
BAEC pretreated with MGO are reduced by 50% after insulin stimulation, 
compared to the control cells. 
Taken together, these results indicate that MGO is able to alter the insulin signal 
transduction and nitric oxide production in endothelial cells. 
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Figure 13: MGO reduces the nitric oxide produced by endothelial cells in response to 
insulin. BAECs were incubated with 500 µM MGO for 16 hours, and stimulated or not with 100 
nM insulin for 10 minutes. After treatment, culture medium was collected and tested for nitric 
oxide concentration by a colorimetric assay. The bars in the graph represent the increase of nitric 
oxide medium content after insulin stimulation, over basal condition. Values are expressed as 
means ± standard deviation of triplicate determinations. Statistical analysis was performed as 
reported in figure 12. 
 
 
Besides inducing the activation of the signal transduction that leads to the 
production of the vasodilator nitric oxide, insulin is also able to induce the release 
of the vasoconstrictor endothelin-1 by endothelial cells, through the activation of 
the MAPK cascade, and then, the endothelin converting enzyme-1 (ECE-1) 
(Kubota et al. 2003). Thus, in order to investigate whether the MAPK pathway as 
well may be altered by MGO, we analyzed the phosphorylation levels of ERK1/2. 
In figure 14 is shown that insulin stimulation induces a 1.7-fold increase of ERK 
phosphorylation in endothelial cells. We found that 16 hours of MGO treatment 
causes a significant increase of ERK phosphorylation in endothelial cells in basal 
conditions,  with no further increase after insulin stimulation. This is an interesting 
finding considering that, in addition to the induction of endothelin-1 release, is 
reported that ERK is also able to phosphorylate IRS-1 on serine and threonine 
residues, thereby inhibiting its function (Gual et al. 2005).     
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Figure 14: ERK activation is increased by MGO incubation. BAECs were treated as reported 
in figure 12. The Western Blot analysis was performed with anti-p-ERK and anti-ERK antibodies. 
Statistical analysis was performed as reported in figure 12. 
 
 
The data described so far show that the incubation of endothelial cells with high 
extracellular concentrations of MGO leads to altered insulin signaling and reduced 
insulin-dependent nitric oxide production, showing that MGO impairs endothelial 
insulin sensitivity. We then decided to investigate the effects of endogenous MGO 
concentration increased by inhibiting the MGO detoxifying enzyme “glyoxalase 
1” (Thornalley 2008). To this aim we performed time course tests treating 
endothelial cells with different concentrations of the glyoxalase inhibitor 
“SpBrBzGSHCp2” (Thornalley et al. 2006). We found that after 48 hours of 
10µM SpBrBzGSHCp2 treatment, insulin signaling is impaired in endothelial 
cells. As shown in figure 15, treatment of BAEC with 10µM SpBrBzGSHCp2 up 
to 48 hours causes a complete loss of insulin-induced phosphorylation of Akt on 
serine 473 (figure 15.a) and of eNOS on serine 1177 (figure 15.b), compared to 
control cells. On the contrary, ERK activation is increased in basal condition 
compared to control cells, and these phosphorylation levels remain unchanged 
after insulin stimulation in cells treated with glyoxalase 1 inhibitor (figure 15.c). 
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Figure 15: The inhibition of glyoxalase 1 by SpBrBzGSHCp2 alters insulin signaling in 
BAECs similarly to the exogenous MGO incubation. BAECs were treated with 10 µM of the 
glyoxalase I inhibitor «SpBrBzGSHCp2» for 48 hours and stimulated or not with 100 nM insulin 
for 10 minutes. Protein lysates obtained from these cells were analyzed by Western Blot assay with 
anti-p-Akt, anti-Akt (a), anti-p-Ser1177-eNOS, anti-eNOS (b), anti-p-ERK and anti-ERK 
antibodies (c), as indicated. To ensure accurate normalization, the same blots were probed with 
anti-tubulin antibody. Statistical analysis was performed as reported in figure 12. 
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Both in the endothelial cells incubated with MGO and in those treated with 
glyoxalase 1 inhibitor, we noticed  the activation of ERK at basal state. This let us 
to hypothesize that ERK could have a role in the harmful effect exerted by MGO 
on the insulin-depedent IRS-1/PI3K/Akt/eNOS pathway activation. In order to 
verify this hypothesis, we inhibited ERK activation pretreating the cells with the 
MEK inhibitor U0126, and then, incubated them with MGO. As demonstrated in 
figure 16, whilst the only incubation of endothelial cells with MGO leads to the 
basal activation of ERK and to the loss of insulin-dependent Akt activation (16.a), 
the total inhibition of ERK is paralleled to a rescue of Akt serine-phosphorylation 
in response to insulin in the cells pretreated with U0126 (16.b).       
 
 
 
Figure 16: The inhibition of ERK restores the insulin-dependent Akt phosphorylation. 
BAECs were pre-incubated with 25 µM of the MEK inhibitor “U0126” for 30 minutes, and then, 
500 µM MGO were added to the culture medium for 16 hours. Next, the cells were stimulated or 
not with 100 nM insulin for 10 minutes. Protein lysates obtained from these cells were analyzed by 
Western Blot assay with anti-p-Akt, anti-Akt (a), anti-p-ERK and anti-ERK antibodies (b), as 
indicated. To ensure accurate normalization, the same blots were probed with anti-14-3-3 antibody. 
Statistical analysis was performed as reported in figure 12. 
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2.2 Effect of MGO on insulin sensitivity in vivo. 
 
In addition to the above reported experiments carried out in vitro in endothelial 
cells, we also investigated the effect of MGO on insulin sensitivity in vivo. To this 
aim, we performed a well established protocol of intraperitoneal administration of 
MGO to C57bl6 mice over 7 weeks (Berlanga et al. 2005). The animals were 
divided into 3 groups, each one including 10 animals: Group 1 included control 
untreated mice; Group 2 mice injected with physiologic solution, and Group 3 
mice injected with MGO solution (see under Materials and Methods). At the end 
of the treatments, insulin tolerance in the three groups of animals was assessed. 
Group 1 and group 2 didn’t show any significant differences of both insulin 
sensitivity and nitric oxide concentration. As shown in figure 17, blood glucose 
levels of Group 3 mice over the 120 min following insulin injection are 
significantly higher than control groups, thus indicating that MGO administration 
induces a systemic insulin resistant state.  
 
 
 
Figure 17: MGO administration impairs insulin sensitivity in vivo. C57BL6 mice were 
peritoneally injected with 50 to 75 mg/kg MGO, or with physiologic solution (CTR), over 5 days 
each week for 7 consecutive weeks. After treatment, ITT were performed. The bars in the graph 
correspond to the area under the curves representing the blood glucose levels of the animals over 
the 2 hours following the insulin injection (0.75 U/kg). Values are expressed as means ± standard 
deviation for 10 mice in each group. 
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Afterward, we analyzed whether MGO may induce endothelium-specific insulin 
resistance, by analyzing insulin-dependent Akt activation in aortae isolated from 
the 3 groups of mice and measuring nitric oxide serum levels. Western blots of 
lysates of aortae from Group 3 revealed a reduction of insulin-induced Akt 
activation (figure 18.a). Moreover, as shown in figure 18.b, in Group 3 insulin 
stimulation of nitric oxide release is reduced by ~2.5 fold compared to control 
groups of mice, suggesting that MGO is able to induce an endothelium-specific 
insulin resistant state also in vivo. 
 
 
 
Figure 18: MGO administration reduces Akt activation in mice isolated aortae and serum 
nitric oxide in C57bl6 mice. C57BL6 mice were treated as described in figure 17. (a) Aortae were 
isolated from the 3 groups of mice, omogenized in JS buffer and the protein extracts analyzed by 
Western Blot with anti-p-Akt and anti-Akt antibodies. (b) 5 animals for each group were 
peritoneally injected with insulin (0.15 U/g), and then, blood was collected. NO serum 
concentration was measured by a colorimetric assay. The bars in the graph represent the increase of 
NO concentration in insulin stimulated mice sera, over not insulin stimulated ones. Values are 
expressed as means ± standard deviation for 10 mice in each group. 
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DISCUSSION 
 
 
 Type 2 diabetes is an important risk factor for the development of 
cardiovascular disease (Schalkwijk  and Stehouwer 2005). This metabolic disorder 
is mainly characterized by peripheral insulin resistance and altered pancreatic β-
cell function. Both these dysfunctions cause hyperglycaemia that, together with 
insulin resistance, plays an important role in the onset and progression of vascular 
dysfunction (Bakker et al. 2009). Several studies have recently highlighted how 
insulin, besides its function as regulator of glucose homeostasis, has important 
nonmetabolic hemodynamic actions (Cersosimo and De Fronzo 2006). As 
demonstrated by Federici et al. (2004), alterations of endothelial insulin pathway 
induce an abnormal production of the vasoregulators ET-1 and NO, and 
consequently, endothelial dysfunction. A widely accepted hypothesis on the 
mechanisms implicated in glucose-mediated vascular damage includes the 
increased production of AGEs (Brownlee 2001; Schalkwijk  and Stehouwer 2005). 
These products result by the formation of covalent bonds between sugars (or 
derivatives) and protein, lipids and nucleic acids, making their function modified. 
Although it has been demonstrated that high AGEs levels are associated to altered 
vasodilation in type 2 diabetes, and that they can inhibit endothelium-dependent 
vasodilation, which specific AGEs are responsible for these effects and which 
molecular pathways are involved remain still unclear.  
In the present study, we sought to investigate the role of MGO, one of the main 
AGEs precursor, in the induction of endothelial insulin resistance. Recent studies 
suggest that MGO may have a role in this sense. Indeed, it has been found that 
higher serum and adipose tissue MGO concentrations are closely related to insulin 
resistance. It has been observed a reduced activation of insulin signaling, in 
particular of IRS-1 phosphorylation, PI3-K activity and glucose uptake in 3T3-L1 
adipocytes treated with MGO (Xuming and Lingyun 2007). Moreover, Riboulet-
Chavey et al. (2006) demonstrated that the exposure of L6 skeletal muscle cells to 
MGO impairs the insulin signaling pathways. However, the effect of MGO on 
insulin signaling in endothelial cell, whose altered function is crucial not only in 
the progression of diabetic vascular complication but also in the worsening of 
peripheral insulin sensitivity, remains to be investigated. In order to explore this 
aspect, we performed a detailed analysis of insulin signal transduction in bovine 
aortic endothelial cells (BAEC) treated with concentrations of MGO that we found 
to be not toxic for the cells, through vitality and apoptosis assays (data not shown). 
Our results show that insulin is not able to induce IRS-1 tyrosine phosphorylation 
in endothelial cells treated with MGO, despite the unchanged levels of the total 
protein content. These data suggest that changes in IRS synthesis/degradation are 
not involved in the impairment of its tyrosine-phosphorylation, since IRS protein 
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levels are unaltered after MGO treatment. MGO is a reactive dicarbonyl molecule 
that can modify lysine and arginine residues in proteins. Recently, we have shown 
that this also occurs in INS-1E cells, as incubation with MGO induces the 
formation of CEL– and argpyrimidine–IRS adducts. Interestingly, on rat IRS-1, 
proximal to YMXM motifs, which have been implicated in p85 binding, Lys602 
near Y608MPM and Arg622 near Y628MPM are found (White 1998; Van 
Obberghen et al. 2001). It is likely that adduct binding to Lys602 and/or Arg622 
could lead to reduced tyrosine phosphorylation of IRS-1/2 resulting in decreased 
p85 anchoring by IRS. An alternative or additional scenario could be a similar 
modification of the Lys and/or Arg residues located within the IRS PH or PTB 
domains, which are essential for optimal IRS tyrosine phosphorylation by IR 
(Fiory et al. 2011). Our future plan is to detect the possible formation of these 
adducts also in endothelial cells, by using antibodies against AGE-adducts.  
One of the main function of phosphorylated tyrosines of IRS proteins is to allow 
the interaction and, consequently, the activation of other proteins, among which 
PI3-K. Indeed, PI3-K is activated by the binding of its regulatory subunit p85 to 
the phosphorylated tyrosine of IRS-1. Thus, we sought to verify whether MGO 
could influence IRS-1/p85 interaction. Consistent with the reduction of IRS-1 
tyrosine phosphorylation, the levels of p85 associated with IRS-1 are not increased 
by insulin-stimulation in endothelial cells treated with MGO. Furthermore, the 
activation of the downstream PI3K effector Akt is reduced as well. Additionally, 
the reduced activation of Akt was followed by the decrease of serine-
phosphorylation of its substrate GSK3β, confirming that Akt kinase activity is 
impaired by MGO. 
As described by Bakker et al. (2009), in addition to the signal cascade leading to 
the production of the vasodilator nitric oxide, insulin binding to its receptor also 
triggers the activation of another branch of insulin signaling, that involves 
activation of MEK, ERK1/2, and endothelin converting enzyme leading to the 
rapid release of ET-1. Interestingly, despite the impaired activation of IRS1/Akt in 
presence of MGO, ERK1/2 appears to be activated already in basal condition by 
MGO incubation, whilst insulin stimulation is not able to induce a further 
significant increase of ERK1/2 phosphorylation. Further investigations are in 
progress to analyze the whole MAPK cascade activation and ET-1 release by 
endothelial cells, in order to clarify whether MGO acts directly on ERK activation, 
or if the latter is activated by the increased activity of  the upstream kinases MEK, 
RAF or IRS-2, and if this leads to an increased ET-1 production as well. Given the 
documented ability of ERK1/2 to phosphorylate IRS-1 on specific serine sites, 
thereby inhibiting its function (Gual et al. 2005; Bard-Chapeau et al. 2005), we 
hypothesized that, through the hyperactivation of ERK1/2, MGO may exert its 
noxious effect on insulin-dependent IRS-1/PI3K/Akt signal transduction. In order 
to validate this hypothesis, we inhibited ERK1/2 phosphorylation by pretreating 
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BAEC with the MEK inhibitor U0126. We found that the inhibition of ERK1/2 
results in a rescue of insulin-dependent Akt phosphorylation, suggesting that 
ERK1/2  iperactivation may play a role in the detrimental effect of MGO on 
PI3K/Akt pathway. Future experiments aiming at analyzing the IRS-1 
phosphorylation on specific serines will allow to confirm whether the 
hypothesized mechanism involving ERK1/2 is pivotal in this MGO-mediated 
effect. However, how MGO may induce ERK1/2 activation in endothelial cells 
remains to be clarified. Several studies report that hyperglycaemia can induce 
glucotoxicity by oxidative stress (Brownlee 2001; Nishikawa et al. 2000), known 
to be causative of ERK activation (Glotin et al. 2006). Guo et al. (2009) 
demonstrated that methylglyoxal induces insulin resistance and salt sensitivity by 
increasing oxidative stress in Sprague-Dawley rats. Whilst recent studies 
demonstrate that MGO leads to oxidative stress in a time and dose dependent 
manner, it has been also shown that MGO causes insulin-resistance in L6 cells at 
time and doses of incubations lower than those necessary to induce oxidative stress 
(Riboulet-Chavey et al. 2006). Thus, we will test whether MGO concentrations 
that induce insulin-resistance in BAEC could also cause ROS increase and if 
oxidative stress is responsible for ERK activation in endothelial cells. 
    Once demonstrated that MGO impairs insulin signaling, we sought to verify 
whether this alteration leads to modification of NO levels produced by endothelial 
cells. NO is a key molecule secreted by endothelium acting and acts as the major 
mediator of insulin action on vascular homeostasis. Evidences suggest that NO 
plays an important role in regulating both blood pressure and glucose levels, thus 
impaired NO availability is pivotal in the development and progression of diabetes 
vascular complications. Indeed, recent studies showed inverse correlation between 
NO level and the diabetic state. Reduced NO availability may not only be of 
relevance to the development of atherosclerotic complications in diabetes, but also 
interferes with insulin-mediated postprandial glucose disposal and possibly 
contributes to the development of insulin resistance (Shiekh et al. 2011). Thus, to 
test the ability of high MGO levels of inducing an altered NO production also in 
vitro in BAEC, we first investigated the activity of eNOS, the enzyme that 
catalyzes the conversion of arginine to citrulline and NO. eNOS activity is 
regulated by phosphorylation at multiple sites, but two of the better-characterized 
sites are serine 1177 (Ser1177) and threonine 495 (Thr495). Ser1177 is rapidly 
phosphorylated by Akt in response to insulin, resulting in increased eNOS activity 
and NO production. By contrast, Thr495 is constitutively phosphorylated in 
endothelial cells, and it is thought to be a negative regulatory site causing a 
decrease in enzyme activity (Fleming and Busse 2003; Andreozzi et al. 2007). We 
found that MGO inhibits insulin induced phosphorylation on eNOS Ser1177 and, 
on the other side, prevents insulin effect on the inhibitory phosphorylation on 
Thr497. Furthermore, the reduced activation of eNOS was paralleled by a 60% 
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reduction of insulin-dependent NO production by BAEC. Taken together, these 
results demonstrate that MGO impairs insulin signaling thereby inhibiting insulin-
mediated NO production by endothelial cells.  
Although in the described experiments we used MGO concentration found to be 
not toxic for BAEC, is reported that the use of millimolar concentrations to 
demonstrate impairment of insulin signalling could be of unlikely physiological 
relevance. For this reason, to investigate the effects of increased MGO 
concentrations, it could be more appropriate to increase endogenous MGO 
concentrations by inhibiting its detoxifying enzyme glyoxalase 1 with specific cell 
permeable inhibitors, or decrease glyoxalase 1 by siRNA techniques (Thornalley 
2008). Thus, we treated BAEC with the glyoxalase 1 inhibitor “SpBrGSHCp2”, 
and we found the complete loss of insulin-stimulated Akt activation and Ser1177-
eNOS phosphorylation, together with a significant increase of ERK1/2 activation 
in basal condition compared to control cells. Interestingly, these results confirmed 
those obtained in BAEC incubated with exogenous MGO. The intracellular MGO 
content in BAEC treated with the glyoxalase 1 inhibitor, together with the activity 
of the enzyme shoul be determinid to confirm reduced activity of the enzyme by 
SpBrGSHCp2 treatment. However, it has been already published that the 
incubation with the same concentrations of the inhibitor (10 μM) over the same 
period of time (48 h) that we used in BAEC, induces a two-fold increase of MGO 
intracellular concentration in HL60 cells (Thornalley et al. 1996). Moreover, 
current studies by Bierhaus et al. report a ~30% reduction of glyoxalase 1 activity, 
corresponding to a two-fold increase of MGO plasma levels, in diabetics compared 
to healthy subjects. These evidence make us confident that our experimental 
conditions have been appropriately chosen. Further investigations are in progress 
to test whether also the balance of NO/ET-1 production by endothelial cells is 
compromised by glyoxalase 1 inhibition.           
In this work we also provide evidence that MGO administration is able to affect 
insulin sensitivity and insulin-dependent serum NO content in vivo. Previous 
studies demonstrated that increased serum and adipose tissue MGO levels in 
fructose-fed rats correlate with the development of insulin-resistance (Xuming and 
Lingyun 2007). Also administration of 1% MGO in drinking water or acute i.v. 
administration of MGO induce insulin resistance and glucose intolerance in 
Sprague-Dowley rats (Guo et al. 2009; Dhar et al. 2010). Moreover, Brouwers et 
al.  (2010) provided evidence that hyperglycaemia-induced impairment of 
endothelium-dependent vasorelaxation is mediated by increased intracellular 
MGO levels, supporting our interest in investigating the role of MGO on 
endothelial function in vivo. 
C57Bl6 mice treated chronically with intraperitoneal injection of MGO become 
insulin resistant compared to untreated mice. This is paralleled by a reduction of 
insulin-induced Akt phosphorylation in aortae isolated from MGO treated mice. 
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As a consequence, MGO-treated mice feature a 3-fold reduction of insulin-induced 
NO serum concentrations compared to control mice, suggesting that MGO is able 
to induce vascular insulin resistance and endothelial disfunction also in vivo.       
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CONCLUSIONS 
 
 
In hyperglycemic conditions, the abnormal accumulation of MGO is related to 
the development of diabetes complications in various tissues and organs. In 
particular, vascular dysfunction causes most of the excess morbidity and mortality 
in diabetes mellitus. This work shows that MGO alters insulin sensitivity in 
vascular tissue in vitro and in vivo. Indeed, both the exogenous MGO incubation 
and the increased intracellular MGO levels, following the glyoxalase 1 inhibition, 
impairs the insulin-mediated activation of IRS-1/PI3K/Akt/eNOS pathway and the 
consequent release of NO by endothelial cells in vitro. On the contrary, MGO 
causes the hyperactivation of ERK at basal state. Interestingly, the inhibition of 
ERK is paralleled to a rescue of Akt activation in response to insulin, suggesting 
that ERK plays a role in the harmful effect exerted by MGO on endothelial 
insulin-sensitivity. These results are strongly supported by data obtained in vivo. 
Indeed, MGO administration to C57 mice reduces insulin-induced Akt activation 
in isolated aortae and NO serum levels. Moreover, insulin tolerance tests show a 
reduced insulin sensitivity in MGO treated mice, compared to controls. 
Further investigations of the molecular mechanisms by which the glucose 
metabolite MGO compromises insulin action in vascular cells may allow to 
develop new strategies to preserve endothelial function in diabetic subjects. 
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Abstract
Aims/hypothesis Beta cell failure is caused by loss of cell
mass, mostly by apoptosis, but also by simple dysfunction
(decline of glucose-stimulated insulin secretion, down-
regulation of specific gene expression). Apoptosis and
dysfunction are caused, at least in part, by lipoglucotoxicity.
The mechanisms implicated are oxidative stress, increase in
the hexosamine biosynthetic pathway (HBP) flux and
endoplasmic reticulum (ER) stress. Oxidative stress plays
a role in glucotoxicity-induced beta cell dedifferentiation,
while glucotoxicity-induced ER stress has been mostly
linked to beta cell apoptosis. We sought to clarify whether
ER stress caused by increased HBP flux participates in a
dedifferentiating response of beta cells, in the absence of
relevant apoptosis.
Methods We used INS-1E cells and murine islets. We
analysed the unfolded protein response and the expression
profile of beta cells by real-time RT-PCR and western blot.
The signal transmission pathway elicited by ER stress was
investigated by real-time RT-PCR and immunofluorescence.
Results Glucosamine and high glucose induced ER stress, but
did not decrease cell viability in INS-1E cells. ER stress
caused dedifferentiation of beta cells, as shown by down-
regulation of beta cell markers and of the transcription factor,
pancreatic and duodenal homeobox 1. Glucose-stimulated
insulin secretion was inhibited. These effects were prevented
by the chemical chaperone, 4-phenyl butyric acid. The
extracellular signal-regulated kinase (ERK) signal transmis-
sion pathway was implicated, since its inhibition prevented
the effects induced by glucosamine and high glucose.
Conclusions/interpretation Glucotoxic ER stress dediffer-
entiates beta cells, in the absence of apoptosis, through a
transcriptional response. These effects are mediated by the
activation of ERK1/2.
Keywords Beta cells . Dedifferentiation . ERK1/2 .
ER stress
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Introduction
Pancreatic beta cell failure is increasingly recognised as
central to progression of type 2 diabetes. Different insults
are implicated in beta cell failure. Results obtained in
rodent models of the disease, and in cultured rodent and
human islet cells show that dyslipidaemia (lipotoxicity) and
hyperglycaemia (glucotoxicity) negatively affect beta cell
function and mass in human type 2 diabetes [1, 2].
One component of beta cell failure in type 2 diabetes is
loss of beta cell mass. Increased apoptosis is, in turn, an
important factor contributing to beta cell loss [3]. The other
component of beta cell failure is beta cell dysfunction,
represented by inhibition of glucose-stimulated insulin
secretion (GSIS) and by downregulation of beta cell-
specific genes resulting in beta cell dedifferentiation.
Several mechanisms have been implicated in glucotoxicity:
the generation of reactive oxygen species (ROS) [4, 5], the
activation of endoplasmic reticulum (ER) stress [6–8] and
an increase in the hexosamine biosynthetic pathway (HBP)
flux [9]. However, these mechanisms are greatly
interconnected. For example, an increased HBP flux causes
hyper-O-glucosamine acylation (GlcNAc) of nuclear and
cytoplasmic proteins [10], oxidative stress [11] and ER
stress. This last mechanism has been demonstrated in cells
other than beta cells [12].
Therefore, it is not clear whether increased HBP flux
causes ER stress in beta cells. Moreover, while it is well
established that ROS play a role in glucotoxicity-induced
beta cell dedifferentiation [11, 13], the notion that
glucotoxicity-induced ER stress participates in beta cell
dedifferentiation has not been established yet. Rather, ER
stress has been mostly associated with beta cell apoptosis
[14, 15], linking its effect to loss of beta cell mass, as is the
case for lipotoxicity-induced ER stress [16, 17]. Beta cells
are particularly susceptible to ER stress, since they
synthesise and secrete large quantities of a single protein.
Proinsulin synthesis represents 30–50% of the total protein
synthesis of the beta cell [18, 19]. In addition, glucose
stimulates proinsulin translation [20], as well as increasing
the stability of pre-proinsulin and transcription of the
insulin gene [21, 22], further increasing the protein load.
Therefore, chronic hyperglycaemia causes persistent acti-
vation of the unfolded protein response (UPR), beta cell
failure and apoptosis. Recently, however, dedifferentiation
has been identified as a new response to ER stress. ER
stress dedifferentiates chondrocytes, downregulating colla-
gen II and aggrecan [23]. These results were confirmed in
vivo in transgenic mice that express mutant collagen X and
in which ER stress produces a chondrodysplasia phenotype
[24]. We have also shown that following ER stress, thyroid
cells dedifferentiate, losing the expression of thyroid-
specific genes and of their transcription factors [25].
In this study we sought to clarify whether increased HBP
flux causes ER stress in beta cells, and whether this ER
stress leads to apoptosis and participates in a dedifferentiat-
ing response of beta cells.
Methods
Materials Media, sera and antibiotics were purchased from
Invitrogen (Paisley, UK). Chemicals were from Sigma-
Aldrich (St Louis, MO, USA). Glucosamine was from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Insulin
was measured by radioimmunoassay (Rat Insulin RIA Kit;
Linco Research, St Louis, MO, USA). Antibodies were
anti-β-actin (monoclonal; Sigma), anti-insulin (Cell
Signaling, Danvers, MA, USA), and anti-binding protein
(BIP)/glucose-regulated protein 78 (GRP78), anti-phospho
extracellular signal-regulated kinase (ERK)1/2, anti-total
ERK1/2 and anti-GLUT2 (Santa Cruz). Collagenase P was
from Roche Applied Science (Penzberg, Germany).
Cell culture and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide assay The clonal beta cell line INS-1E
was used between passages 54 and 95. INS-1E cells were
cultured in a humidified atmosphere containing 5% (vol./vol.)
CO2 in complete medium composed of RPMI 1640
supplemented with 5% (vol./vol.) heat-inactivated FCS,
1 mmol/l sodium pyruvate, 50 μmol/l 2-mercaptoethanol,
2 mmol/l glutamine, 10 mmol/l HEPES, 100 U/ml penicillin
and 100 μg/ml streptomycin. The maintenance culture was
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split once a week and cells were seeded at 3×106 cells/
75 cm2 in Falcon bottles (BD Biosciences Labware, Franklin
Lakes, NJ, USA). The potential presence of mycoplasma
was regularly checked using a photometric enzyme immu-
noassay (Roche, Penzberg, Germany). For most experiments,
INS-1E were seeded at 2×105 cells/ml in Falcon 24 well
plates and used 4 to 5 days thereafter, with one medium
change on day 3 or 4. Cell viability was measured by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay as previously reported [26].
Real-time RT-PCR Total RNA was isolated from INS-1E
cells and islets using a kit (RNeasy; Qiagen Sciences,
Valencia, CA, USA). For real-time RT-PCR analysis, 1 μg
RNA was reverse-transcribed using Superscript II Reverse
Transcriptase (Invitrogen, Carlsbad, CA, USA). PCRs were
analysed using SYBR Green mix (Invitrogen). Reactions
were performed using Platinum SYBR Green quantitative
PCR Super-UDG (BioRad, Hercules, CA, USA) and a real-
time PCR detection system (iCycler IQ multicolour;
BioRad). All reactions were performed in triplicate and
cyclophilin was used as an internal standard. The primer
sequences are shown in the electronic supplementary
material (ESM) Table 1.
Insulin secretion GSIS was tested in INS-1E cells between
passages 54 and 95. Before the experiments, cells were
maintained for 2 h in glucose-free medium. The cells were
then washed twice and preincubated for 30 min at 37°C in
glucose-free KRB HEPES buffer (KRBH, 135 mmol/l CaCl2,
3.6 mmol/l KCl, 5 mmol/l NaHCO3, 0.5 mmol/l NaH2PO4,
0.5 mmol/l MgCl2, 1.5 mmol/l CaCl2 and 10 mmol/l HEPES,
pH 7.4). BSA (0.1%, wt/vol.) was added as an insulin carrier.
Next, cells were washed once with glucose-free KRBH and
then incubated for 30 min in KRBH and stimuli as indicated.
Incubation was stopped on ice and the supernatant fractions
collected for insulin secretion, which was measured by RIA
using rat insulin as standard.
Western blot Western blots were carried out as previously
reported [27].
Immunofluorescence Immunofluorescence experiments
were performed as previously reported [25].
Islet isolation and ex vivo insulin secretion Islets were
isolated from 6-month-old C57Bl/6J mice. Animals were
killed by cervical dislocation, the fur was soaked with
ethanol and the abdomen was opened. The pancreas was
inflated by KRBH injection and excised. The excised
pancreas was washed twice with KRBH and digested
with collagenase in a water bath (37°C), shaken by
hand for 5–8 min. The digested pancreas was treated
with Dnase I. The islets were handpicked under a
stereo-microscope and cultured for 24 h in complete
RPMI 1640 medium. For glucose-induced insulin re-
lease, 20 size-matched islets were preincubated at 37°C
for 30 min in KRBH and then incubated for 1 h in a
shaking water bath at 37°C; incubation was with 500 μl
KRBH medium containing 2.8 mmol/l glucose or
2.8 mmol/l glucose plus 16.7 mmol/l glucose. Islets
were then pelleted and supernatant fractions collected
for measurement of insulin secretion. Insulin concen-
trations were determined by RIA. Experiments involving
animals were conducted in accordance with the Princi-
ple of Laboratory Care.
Statistical procedures All data are presented as mean±SE.
Statistical differences were determined by one-way or two-
way ANOVA as appropriate, and Bonferroni’s post hoc
testing was performed when applicable. A value of p<0.05
was considered to be significant.
Results
Glucosamine and glucose induce ER stress in INS-1E
cells The induction of mRNA encoding the diagnostic UPR
marker Bip/Grp78 was examined by real-time RT-PCR
after exposure to various concentrations of glucosamine
(2.5, 5.0, 7.5 and 10.0 mmol/l; Fig. 1a) and glucose
(25 mmol/l; Fig. 2a) for 24 h. Glucosamine dose-
dependently induced Bip mRNA, with a maximal effect at
7.5 and 10.0 mmol/l (Fig. 1a), and a similar effect at 24 and
48 h (Fig. 1b). As a control for the osmotic effects of these
treatments, cells were exposed to 5.0 and 25 mmol/l xylose,
which showed no effect (Fig. 1a). As a positive control,
INS-1E cells were treated with the widely used inductor of
ER stress, tunicamycin. Interestingly, tunicamycin showed
a quantitatively similar effect to that of glucosamine
(Fig. 1c). Accordingly, BIP protein was induced to a
similar degree by glucosamine and tunicamycin (Fig. 1d).
Glucosamine (and tunicamycin) also increased the
mRNA levels of other ER stress markers, such as Chop
(Fig. 1e), spliced (active) Xbp1 (Fig. 2d) and Atf6 (Fig. 2e),
suggesting that the three major branches of the UPR were
activated by glucosamine. However, glucosamine did not
decrease viability of INS-1E cells, suggesting that apoptosis
was not significantly activated (Fig. 1f). Tunicamycin had
an effect similar to that of glucosamine on Chop, spliced
Xbp1 and Atf6 mRNA (Figs 1e and 2d, e).
The ability of azaserine or 6-diazo-5-oxo-norleucine (not
shown), which are potent inhibitors of glutamine:fructose-
6-phosphate amidotransferase (GFAT), to attenuate glucose-
but not glucosamine-induced ER stress (Fig. 2a) suggests
that elevated concentrations of glucose caused ER stress
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through a glucosamine intermediate. Glucosamine can
promote the O-GlcNAc modification of intracellular pro-
teins. O-GlcNAc levels can also be increased by treatment of
cells with O-(2-acetamido-2-deoxy-D-glucopyranosylidene)
amino-N-phenylcarbamate (PUGNAc), an inhibitor of O-
GlcNAcase. However, PUGNAc treatment did not promote
ER stress (Fig. 2a). Thus, we cannot conclude that glucos-
amine causes ER stress via increased protein O-GlcNAc
levels, although this mechanism cannot be ruled out.
Chemical chaperones are a group of compounds that can
stabilise protein conformation and improve ER folding
capacity. We sought to test whether ER stress induced by
glucosamine and high glucose in beta cells is, in fact,
alleviated by chemical chaperones. As shown in Fig. 2a–e,
4-phenyl butyric acid (PBA) was able to inhibit activation of
glucosamine-, high glucose- (and tunicamycin-) induced ER
stress markers. Therefore, PBA could be used to investigate
the causal relationship between glucosamine-induced ER
stress and beta cell dedifferentiation (see below).
To evaluate whether glucosamine- and high glucose-
induced ER stress could be mediated by oxidative stress,
INS-1E cells were pretreated with the glutathione precursor
N-acetylcysteine (NAC) (Fig. 2a–c). NAC was not able to
inhibit the glucosamine- and high glucose-induced increase
of Bip and Chop mRNA, suggesting that glucosamine- and
high glucose-induced ER stress was not dependent on
oxidative stress in INS-1E beta cells.
Glucosamine-induced ER stress inhibits differentiation of
INS-1E To examine the effects of HBP activation on beta
cell function, we examined the expression of two beta cell
markers, Glut2 and Ins1. Glucosamine treatments, which
are able to trigger ER stress, downregulated the expression
of Glut2 (Fig. 3a, b) and Ins1 (Fig. 3c). To gain insights
into the mechanism of downregulation of Glut2 and Ins1,
we analysed the expression of a transcriptional regulator of
both genes, the homeobox transcription factor Pdx1. As
shown in Fig. 3d, Pdx1 was downregulated by glucosamine
treatment. These results suggest that Glut2 and Ins1 were
transcriptionally downregulated by glucosamine-induced
ER stress and that the downregulation of Pdx1 participated
in this effect.
To test the functionality of the beta cell following
glucosamine-induced ER stress, we measured GSIS in
control and glucosamine-treated INS-1E cells. In compar-
ison with untreated cells, glucosamine-treated cells had a
significantly reduced GSIS (Fig. 3e), showing that glucos-
amine alters the insulin secretory response of normal beta
cells to glucose.
The glucosamine-induced dedifferentiation of INS-1E cells
is suppressed by the chemical chaperone PBA To establish
a causal relationship between glucosamine-induced ER
stress and the decreased differentiation of INS-1E cells,
we used pre-treatment with PBA, which alleviated the
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Fig. 1 Glucosamine induces ER stress but does not affect cell
viability in INS-1E cells. a INS-1E cells were treated with the
indicated concentrations of glucosamine (GlcN) or xylose, or (b, d, e)
with 7.5 mmol/l glucosamine or (c, d, e) 0.5 μg/ml tunicamycin (Tun)
for times as indicated. Bip/Grp78 (a–c) and Chop (e) mRNA was
determined by real-time RT-PCR analysis of total RNA isolated from
INS-1E, using cyclophilin as internal standard. mRNA levels in
treated cells are relative expression units (REU) to those in control
cells. Values are mean±SD; n=6; *p<0.05, **p<0.01 and ***p<
0.001. d INS-1E cells treated with 0.5 μg/ml tunicamycin or
7.5 mmol/l glucosamine for the indicated times were solubilised and
equal amounts of protein (40 μg/sample) were analysed by western
blotting using BIP/GRP78- or β-actin-specific antibodies, with BIP
and actin from the same gel; n=3. f MTT assay for cell viability (48 h
treatment) in INS-1E cells; results are percentage of the control (n=3)
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glucosamine-induced ER stress (Fig. 2b–e). PBA reversed
the effect of glucosamine on Glut2 mRNA (Fig. 4a), Ins1
mRNA (Fig. 4b), Pdx1 mRNA (Fig. 4c) and GSIS
(Fig. 3e). These results indicate that glucosamine-induced
ER stress causally decreases differentiation of INS-1E cells.
Since oxidative stress is another important determinant of
beta cell damage, we checked for its involvement in
glucosamine-induced ER stress. However, pre-treatment
with NAC did not prevent the glucosamine-induced down-
regulation of beta cell markers (Fig. 4a–c).
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Fig. 2 High glucose induces ER stress and UPR through activation of
the hexosamine pathway in INS-1E cells. High glucose-/glucosamine
(GlcN)-induced ER stress is reversed by the chemical chaperone PBA,
but not by the antioxidant NAC. a INS-1E cells were pre-treated or
not with 5 μmol/l azaserine (Aza) for 20 min, or (a–e) with 2.5 mmol/l
PBA or (a–c) 1 mmol/l NAC for 24 h, followed by 24 h culture in
the presence of glucose, PUGNAc or GlcN (a) as indicated, or of
7.5 mmol/l glucosamine (b–e) or 0.5 μg/ml tunicamycin (Tun) (d, e)
for 24 h. Bip/Grp78 (a, b), Chop (c), spliced Xbp1 (d) and Atf6 (e)
mRNA in treated cells was determined by real-time RT-PCR analysis
using cyclophilin as internal standard and is quantified in relative
expression units (REU) vs control cells; values mean±SD; n=5; *p<
0.05, **p<0.01, ***p<0.001
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Since chemical chaperones prevented glucosamine-
induced ER stress and glucosamine-induced downregula-
tion of Ins1, Glut2 and Pdx1 mRNA, we sought to
determine whether PUGNAc, which was unable to induce
ER stress, was also unable to induce beta cell dedifferen-
tiation. As shown in Fig. 4a–c, treatment of INS-1E cells
with PUGNAc did not cause dedifferentiation, thus
strengthening the notion that ER stress was the cause of
loss of differentiation.
The glucosamine-induced dedifferentiation of INS-1E cells
is mediated by activation of the mitogen-activated protein
kinase/ERK kinase–ERK pathway To obtain insights into
the signal transmission pathway linking glucosamine-
induced ER stress and beta cell dedifferentiation, we
analysed the effect of specific inhibitors of pathways
emanating from the stressed ER [28]. We began by using
SB203580 to inhibit p38 mitogen-activated protein kinase
(MAPK). SB203580 pretreatment had no effect on
glucosamine-induced Ins1 and Pdx1 mRNA downregula-
tion evaluated by real-time RT-PCR (not shown). Next, we
used U0126, a specific inhibitor of MAPK/ERK kinase
(MEK)1/2. In this case, U0126 not only completely
reversed the effect of glucosamine, but even increased
mRNA expression of Ins1, Glut2 and Pdx1 in the control
condition (Fig. 5a). Therefore, it appears that MEK1/2,
probably through phosphorylation of ERK1/2, exerts an
inhibitory effect on Ins1 and Glut2 expression under basal
conditions and following glucosamine treatment. In addi-
tion to this inhibitory effect, MEK1/2 also seems to
contribute to decreased expression of Pdx1.
Next, we sought to determine whether glucosamine treat-
ments activated ERK1/2 and whether U0126 prevented such
activation. As shown in Fig. 5b, c, glucosamine induced an
approximately twofold increase in phosphorylated ERK1/2
at 24 h (the effect being evident as early as 6 h and lasting at
least 48 h, data not shown). PBA blocked ERK activation by
glucosamine. U0126 not only prevented the increase of
phosphorylated ERK1/2, but also inhibited the basal levels
of activation of ERK1/2. Notably, BIP induction by
glucosamine was not affected by U0126 pretreatment,
indicating that U0126 did not prevent ER stress (Fig. 5d).
Moreover, U0126 almost completely restored glucosamine-
inhibited GSIS (Fig. 5e). Finally, immunofluorescence
experiments confirmed that U0126 was not only able to
prevent the downregulation of total insulin levels (the
antibodies used react with insulin and proinsulin), but also
to increase this level above the control value (Fig. 5f–g).
High glucose-induced ER stress displays similar effects to
glucosamine-induced ER stress As shown in Fig. 6, high
glucose-induced ER stress was also able to dedifferentiate
INS-1E cells (Glut2, Ins1 and Pdx1 mRNA). These effects
were reversed by azaserine, PBA and U0126, suggesting
that they were dependent on increased HBP flux, ER stress
and ERK activation, respectively; however, the effects were
not reversed by NAC, suggesting that they were indepen-
dent of oxidative stress. GSIS was inhibited by high
glucose, an effect that was reversed by azaserine, PBA
and U0126, but not by NAC (Fig. 6d).
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Fig. 4 PBA, but not NAC reversed the dedifferentiating effect of
glucosamine. INS-1E cells were pre-treated or not with 2.5 mmol/l
PBA or 1 mmol/l NAC for 24 h and then cultured in the presence of
7.5 mmol/l glucosamine (GlcN) or 20 μmol/l PUGNAc for 24 h.
a Glut2, (b) Ins1 and (c) Pdx1 mRNA was determined by real-time
RT-PCR analysis of total RNA isolated from INS-1E cells, using
cyclophilin as internal standard. mRNA levels in treated cells are
quantified as relative expression units (REU) vs control cells; values
are mean±SD; n=3; *p<0.05, **p<0.01, ***p<0.001
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Glucosamine induces ER stress and dedifferentiates primary
mouse islets in a manner that is dependent on ER stress and
ERK Next, we sought to determine whether the dedifferen-
tiating effect of glucosamine was also present in primary
mouse islets. To this end, we first evaluated whether
glucosamine was able to induce ER stress in this system.
As shown in Fig. 7a, b, 7.5 mmol/l glucosamine induced
Bip and Chop mRNAs with a time course similar to that
seen in INS-1E cells. Thus, at 24 h the effect of
glucosamine was already maximal (Fig. 7a, b). Next, we
investigated the effect of glucosamine on beta cell genes
Glut2 and Ins1. In a manner that was reciprocal to Bip and
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Fig. 5 Role of phosphorylation of ERK 1/2 on glucosamine-induced
dedifferentiation in INS-1E cells. INS-1E cells were pretreated or not
with 10 μmol/l U0126 for 1 h (a, b, d, e) and then treated (a–f) with
7.5 mmol/l glucosamine (GlcN) for 24 h. a mRNAwas determined by
real-time RT-PCR analysis of total RNA isolated from INS-1E cells,
using cyclophilin as internal standard. mRNA levels in treated cells
are quantified as relative expression units (REU) vs control cells;
values are mean±SD; n=3; *p<0.05, **p<0.01, ***p<0.001. b–d
Cells were solubilised and equal amounts of proteins (40 μg/sample)
were analysed by western blotting using antibodies to phosphorylated
(P)-ERK 1/2 and ERK 1/2 (b, c), and (d) to BIP/GRP78 or β-actin (n=
5). e Glucose-stimulated insulin release was assayed by RIA in the
culture medium; values are mean±SD; n=4; *p<0.05, **p<0.01. f INS-
1E cells were stained with antibodies (Ab) against insulin (green).
Following glucosamine treatment, the signal for insulin decreased,
compared with untreated control cells. However, pre-treatment for 1 h
with 10 μmol/l U0126 not only prevented the decrease, but also
increased insulin levels above those of control. g Quantification of three
different experiments was performed with the software package of a
confocal microscope (LSM 510 META; Zeiss, Oberkochen, Germany)
*p<0.05, **p<0.01
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Chop mRNA induction, Glut2 and Ins1 mRNA down-
regulation was maximal as early as 24 h (Fig. 7c, d), again
mimicking the results obtained in INS-1E cells. Also in
primary islets, the inhibitory effect of glucosamine on Glut2
and Ins1 mRNA is likely to have been transcriptional, as
glucosamine also downregulated Pdx1 mRNA (Fig. 7e).
Moreover, GSIS was reduced in islets treated with glucos-
amine, suggesting that there was also a functional defect in
the secretion machinery of islets (Fig. 7f). Finally, these
effects were dependent on phosphorylation of ERK, since
they were reversed by pretreatment with U0126 (Fig. 7g, h).
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Fig. 6 High glucose-induced
ER stress displays similar effects
to those of glucosamine-induced
ER stress. INS-1E cells were
pre-treated or not with
5 μmol/l azaserine (Aza) for
20 min, 10 μmol/l U0126 for
1 h, and 2.5 mmol/l PBA and
1 mmol/l NAC for 24 h, followed
by 24 h culture in the presence of
25 mmol/l glucose. mRNA for
Glut2 (a), Ins1 (b) and Pdx1 (c)
was determined by real-time
RT-PCR analysis of total RNA
isolated from INS-1E cells,
using cyclophilin as internal
standard. mRNA levels in
treated cells are quantified as
relative expression units (REU)
vs control cells; values are
mean±SD; n=3. d GSIS was
assayed by RIA in the culture
medium; values are mean±SD;
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Fig. 7 Effects of glucosamine in isolated mice islets. Islets isolated
from 6-month-old mice were pre-treated or not with 2.5 mmol/l PBA
for 24 h (f) or with 10 μmol/l U0126 for 1 h (g, h), followed by
treatment for 1 day (a–h) with 7.5 mmol/l glucosamine (GlcN). a Bip/
Grp78, (b) Chop, (c, g) Glut2, (d, g) Ins1 and (e, g) Pdx1 mRNAwas
determined by real-time RT-PCR analysis of total RNA isolated from
mice islets, using cyclophilin as internal standard. mRNA levels in
treated cells are quantified as relative expression units (REU) vs
control; values are mean±SD; n=4; *p<0.05, **p<0.01 and ***p<
0.001. f, h GSIS was examined over 30 min with batches of 20 islets,
comparing 3.3 mmol/l with 20 mmol/l (+) glucose. Islets were
subsequently collected by centrifugation at 1500 g and supernatant
fractions assayed for insulin content by RIA. Values are mean±SD;
n=3; **p<0.01
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Discussion
In this study, we show that glucosamine and high glucose
induced ER stress in INS-1E cells and in murine islets. As a
result, the expression of beta cells markers was decreased
and GSIS was inhibited. These deleterious consequences of
glucosamine and high glucose treatment were fully pre-
vented by the chemical chaperone PBA, but not by the
antioxidant NAC. The effect of glucosamine- and high
glucose-induced ER stress on beta cell differentiation and
function appears to be mediated by the MEK–ERK
pathway.
The declining function and mass of the pancreatic beta
cells is central to the progression of type 2 diabetes. While
it is well established that dyslipidaemia and hyperglycaemia
contribute to beta cell dysfunction [1, 2], the molecular
mechanisms implicated are far less clear. In particular, the
adverse action of glucose on beta cells is much less well
understood, being slower and more subtle than that of fatty
acids, which cause strong ER stress and subsequent
apoptosis. High glucose has been reported to cause
generation of ROS [4, 5], activation of ER stress [6–8]
and increase in the HBP flux [9]. Under physiological
conditions, only 1–3% of intracellular glucose enters the
hexosamine pathway; however, the flux increases with
glucose concentration [9]. Increased HBP flux, in turn,
causes hyper-O-GlcNAc of proteins [10], oxidative stress
[11] and ER stress, although this last mechanism has been
demonstrated in cells other than beta cells [12, 29].
We have demonstrated that glucose and glucosamine
promote ER stress in beta cells. From our data, we cannot
conclude that glucosamine causes ER stress via increased
protein O-GlcNAc levels, although this mechanism cannot
be ruled out. In fact, data from the literature support the
existence of mechanisms that are dependent on [30] and
independent of [31] protein O-GlcNAc. Our results also
suggest that a glucosamine intermediate is involved in ER
stress induction, as inhibition of glutamine amidotrans-
ferases, including GFAT, by azaserine blocked ER stress
induction by high glucose but not by glucosamine.
ER stress is recognised as an important determinant
of type 2 diabetes, and is a central feature of peripheral
insulin resistance, acting by inhibiting insulin receptor
signalling. However, ER stress also plays an important
role in the beta cell failure that precipitates type 2
diabetes. Beta cells, like plasma cells and thyroid cells,
have a high protein load [32, 33], synthesising large
quantities of (a single) protein. Proinsulin represents up to
20% of the total mRNA and 30–50% of the total protein
synthesis of the beta cell [18, 19]. These percentages
increase further, when considering only cargo (secretory
and membrane) proteins synthesised by the beta cell. In
addition, glucose stimulates proinsulin translation [20],
and increases the stability of pre-proinsulin and transcrip-
tion of the insulin gene [21, 22], further increasing the
protein load. Therefore, beta cells are highly susceptible to
ER stress.
The ER stress induced by high glucose/glucosamine is
mild, in contrast to that induced by fatty acids and Ca2+-
perturbing drugs. Accordingly, we did not detect a
significant effect of glucosamine on the viability of INS-
1E cells, while ER stress induced by fatty acids [17] and the
Ca2+-perturbing drug cyclopiazonic acid [34] is followed
by massive apoptosis. However, the activation of HBP flux,
even in the absence of relevant apoptosis, has deleterious
effects on beta cells, causing ER stress and inhibiting beta
cell differentiation. High glucose-/glucosamine-induced ER
stress and beta cell dedifferentiation are causally linked, as
demonstrated by the effect of PBA. Indeed, pretreatment
with PBA prevented ER stress and dedifferentiation of beta
cells. In general, adaptation or apoptosis are believed to be
the major outcomes of ER stress. However, dedifferentia-
tion has recently been identified as a new response to ER
stress. It has been shown that ER stress dedifferentiates
chondrocytes, downregulating collagen II and aggrecan
[23]. In vivo, in transgenic mice expressing mutant collagen
X, ER stress altered chondrocyte differentiation [24].
Chondrocytes survive ER stress, but terminal differentiation
is interrupted. Thyroid cells subjected to ER stress down-
regulate thyroid-specific markers and their transcriptional
factors [25]. Dedifferentiation may constitute a new tactic
for survival, since cells avoid energy expenditure for the
expression of genes that, in this condition, are unnecessary
or even dispensable. Moreover, in all cited cases [23–25],
as well as in the case of beta cells (this study), the
differentiation genes encode cargo proteins, resulting in a
reduction of ER-specific protein load. This represents a
selective and long-term downregulation, which is tempo-
rally distinct from the general and short-term shut-off of
protein synthesis elicited by (PKR)-like endoplasmic
reticulum kinase (PERK) [35]. The mechanism of this
downregulation is, at least in part, transcriptional, since
downregulation of Ins1 and Glut2 is accompanied by the
coordinate downregulation of Pdx1.
Our results indicate that ER stress induced by HBP
flux triggers signalling via the MEK–ERK pathway to
elicit dedifferentiation of beta cells. It is well known that
glucose regulates insulin transcription. Acute exposure of
beta cells to high glucose stimulates insulin transcription,
while chronic exposure to high glucose results in
inhibition of the insulin gene promoter activity. Both
effects are mediated by phosphorylation of ERK1/2 [36].
Downstream of ERK1/2 there are several factors that bind
to the insulin gene promoter to enhance transcription in
response to glucose [37]. Pancreatic and duodenal homeo-
box 1 (PDX1) and beta cell E-box transcriptional activator
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2 (BETA2) synergistically activate insulin gene transcrip-
tion [38]. v-Maf musculoaponeurotic fibrosarcoma onco-
gene family, protein A (avian) (MAFA) also contributes to
glucose responsiveness [39]. Negative regulators of
insulin promoter activity include Jun and the CCAAT/
enhancer binding protein β (C/EBP-β). These transcrip-
tion factors are increased in beta cells during prolonged
exposure to low and high glucose, respectively [40, 41].
ERK1 and 2 are activated in pancreatic beta cells by
stimulatory concentrations of glucose, this activation
being Ca2+-dependent [42, 43]. A rise in intracellular
Ca2+ is secondary to glucose metabolism and cell
depolarisation. Moreover, activation of ERK1/2 by glu-
cose is sensitive to inhibitors of calmodulin and the class
2B Ca2+/calmodulin-dependent phosphatase, calcineurin
[44]. Hence, calcineurin is an upstream regulator of the
ERK1/2 pathway in pancreatic beta cells. More recently a
possible mechanism linking glucose, Ca2+ and ERK activa-
tion has been elucidated. The protein phosphatase calcineurin
selectively dephosphorylates kinase suppressor of Ras 2
(KSR2) in response to Ca2+ signals, regulating KSR2
localisation and ERK scaffold activity [45].
However, besides Ca2+- and calcineurin-mediated mech-
anisms, our study suggests that ER stress may play a role.
This may occur specifically during chronic hyperglycaemia.
Thus, it is known that chronic challenge of islets with high
glucose causes a reduction of Ca2+ influx induced by
glucose and diazoxide compared with control islets and,
moreover, does not lead to detectable changes in the
intracellular Ca2+ concentration [46]. Therefore, in chronic
hyperglycaemia, the Ca2+-mediated mechanisms of ERK
activation are likely to be much less involved. Instead,
prolonged exposure of beta cells to high glucose or
glucosamine induces ER stress. Following the stress, ERK
is activated through inositol-requiring 1 (IRE1)-dependent
mechanisms [27]. This long term ERK activation may
inhibit proinsulin transcription by the already described,
mainly post-translational mechanisms. BETA2, PDX1,
MAFA, NFAT and C/EBP-β are ERK1/2 substrates [36,
47, 48]. The latter three associate with the insulin gene
promoter in an ERK1/2-dependent manner [36]. Finally, the
transactivating activities of BETA2 and PDX1 depend at
least partly on ERK1/2 activity [49]. Moreover, the present
study suggests that, in addition to those known mechanisms
in the regulation of insulin transcription, inhibition (prob-
ably transcriptional) of an important beta cell transcriptional
factor, PDX1, may also play a role.
Interestingly, U0126 not only prevented the glucosamine
stimulation of ERK1/2 phosphorylation, but also inhibited
the phosphorylation of ERK1/2 present in the basal
condition. This effect is paralleled by prevention of the
inhibitory effect of glucosamine on Ins1 and Pdx1 mRNA,
and on total insulin protein (as detected by immunofluo-
rescence), and also by an increase of these mRNAs and
total insulin protein levels above those present in basal
conditions. It has been proposed recently that cells with a
high protein load, such as beta cells, have a level of
‘physiological’ UPR activation that balances the high
protein load with the folding capability [50]. It is
conceivable that this ‘physiological’ UPR causes a certain
level of ERK activation. This, in turn, may basally inhibit
insulin transcription. In this model, insulin load and
‘physiological’ UPR activation exert a feedback loop at
the level of insulin transcription, in addition to the loop at
the translational level, which is operated by PERK–
eukaryotic translation initiation factor 2A (eIF2α).
Acknowledgements This work was supported by grant 2006069102_
004 of MIUR to B. Di Jeso, as well as by the EFSD and the
European Community’s PREPOBEDIA (201681). The financial
support of Telethon, Italy to F. Beguinot is acknowledged.
Contribution statement AL, LU, AST, CN, LP, DDL, GN, CG,
FB, CM analysed the data. AL, LU, AST, CN, LP, DDL, GN, CG, FB,
CM revised the article critically. BDJ conceived and designed the
study, and wrote the article. All authors approved the final version of
the paper to be published.
Duality of interest The authors declare that there is no duality of
interest associated with this manuscript.
References
1. Donath MY, Halban PA (2004) Decreased beta-cell mass in
diabetes: significance, mechanisms and therapeutic implications.
Diabetologia 47:581–589
2. Kaiser N, Leibowitz G, Nesher R (2003) Glucotoxicity and beta-
cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab
16:5–22
3. Rhodes CJ (2005) Type 2 diabetes—a matter of beta-cell life and
death? Science 307:380–384
4. Robertson RP (2004) Chronic oxidative stress as a central
mechanism for glucose toxicity in pancreatic islet cells in
diabetes. J Biol Chem 279:42351–42354
5. Kaneto H, Nakatani Y, Kawamori D et al (2005) Role of oxidative
stress, endoplasmic reticulum stress, and c-Jun N-terminal kinase
in pancreatic beta cell dysfunction and insulin resistance. Int J
Biochem Cell Biol 37:1595–1608
6. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL (2005)
Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes:
many differences, few similarities. Diabetes 54:S97–S107
7. Elouil H, Bensellam M, Guiot Y et al (2007) Acute nutrient
regulation of the unfolded protein response and integrated stress
response in cultured rat pancreatic islets. Diabetologia 50:1442–
1452
8. Eizirik DL, Cardozo AK, Cnop M (2008) The role for
endoplasmic reticulum stress in diabetes mellitus. Endocr Rev
29:42–61
9. Hanover JA, Lai Z, Lee G, Lubas WA, Sato SM (1999) Elevated
O-linked N-acetylglucosamine metabolism in pancreatic beta-
cells. Arch Biochem Biophys 362:38–45
Diabetologia
10. Park J, Kwon H, Kang Y, Kim Y (2007) Proteomic analysis
of O-GlcNAc modifications derived from streptozotocin and
glucosamine induced beta-cell apoptosis. J Biochem Mol Biol
40:1058–1068
11. Kaneto H, Xu G, Song KH et al (2001) Activation of the
hexosamine pathway leads to deterioration of pancreatic beta-cell
function through the induction of oxidative stress. J Biol Chem
276:31099–31104
12. Qiu W, Kohen-Avramoglu R, Mhapsekar S, Tsai J, Austin RC,
Adeli K (2005) Glucosamine-induced endoplasmic reticulum
stress promotes ApoB100 degradation: evidence for Grp78-
mediated targeting to proteasomal degradation. Arterioscler
Thromb Vasc Biol 25:571–577
13. Harmon JS, Stein R, Robertson RP (2005) Oxidative stress-
mediated, post-translational loss of MafA protein as a contributing
mechanism to loss of insulin gene expression in glucotoxic cells.
J Biol Chem 280:11107–11113
14. Oyadomari S, Araki E, Mori M (2002) Endoplasmic reticulum
stress-mediated apoptosis in pancreatic beta cells. Apoptosis
7:335–345
15. Fonseca SG, Burcin M, Gromada J, Urano F (2009) Endoplasmic
reticulum stress in beta cells and development of diabetes. Curr
Opin Pharmacol 9:763–770
16. Cnop M, Ladriere L, Hekerman P et al (2007) Selective inhibition
of eukaryotic translation initiation factor 2 alpha dephosphoryla-
tion potentiates fatty acid-induced endoplasmic reticulum stress
and causes pancreatic beta cell dysfunction and apoptosis. J Biol
Chem 282:3989–3997
17. Cunha DA, Hekerman P, Ladrière L et al (2008) Initiation and
execution of lipotoxic ER stress in pancreatic beta cells. J Cell Sci
121:2308–2318
18. van Lommel L, Janssens K, Quintens R et al (2006) Probe-
independent and direct quantification of insulin mRNA and
growth hormone mRNA in enriched cell preparations. Diabetes
55:3214–3220
19. Schuit FC, Kiekens R, Pipeleers DG (1991) Measuring the
balance between insulin synthesis and insulin release. Biochem
Biophys Res Commun 178:1182–1187
20. Wicksteed B, Uchizono Y, Alarcon C, McCuaig JF, Shalev A,
Rhodes CJ (2007) A cis-element in the 5′ untranslated region of
the preproinsulin mRNA (ppIGE) is required for glucose
regulation of proinsulin translation. Cell Metab 5:221–227
21. Leibiger B, Moede T, Schwarz T et al (1998) Short-term
regulation of insulin gene transcription by glucose. Proc Natl
Acad Sci USA 95:9307–9312
22. German M, Ashcroft S, Docherty K et al (1995) The insulin gene
promoter. A simplified nomenclature. Diabetes 44:1002–1004
23. Yang L, Carlson SG, McBurney D, Horton WE Jr (2005) Multiple
signals induce endoplasmic reticulum stress in both primary and
immortalized chondrocytes resulting in loss of differentiation,
impaired cell growth, and apoptosis. J Biol Chem 280:31156–
31165
24. Tsang KY, Chan D, Cheslett D et al (2007) Surviving endoplasmic
reticulum stress is coupled to altered chondrocyte differentiation
and function. PLoS Biol 5:568–585
25. Ulianich L, Garbi C, Treglia AS et al (2008) ER stress is associated
with dedifferentiation and an epithelial-to-mesenchymal transition-
like phenotype in PC Cl3 thyroid cells. J Cell Sci 121:477–486
26. De Vitis S, Treglia AS, Ulianich L et al (2011) Tyr phosphatase-
mediated P-ERK inhibition suppresses senescence in EIA + v-raf
transformed cells, which, paradoxically, are apoptosis-protected in
a MEK-dependent manner. Neoplasia 13:120–130
27. Di Jeso B, Park YN, Ulianich L et al (2005) Mixed-disulfide
folding intermediates between thyroglobulin and endoplasmic
reticulum resident oxidoreductases ERp57 and protein disulfide
isomerase. Mol Cell Biol 25:9793–9805
28. Nguyên DT, Kebache S, Fazel A et al (2004) Nck-dependent
activation of extracellular signal-regulated kinase-1 and regulation
of cell survival during endoplasmic reticulum stress. Mol Biol
Cell 15:4248–4260
29. Raciti GA, Iadicicco C, Ulianich L et al (2010) Glucosamine-
induced endoplasmic reticulum stress affects GLUT4 expression
via activating transcription factor 6 in rat and human skeletal
muscle cells. Diabetologia 53:955–965
30. Vosseller K, Wells L, Lane MD, Hart GW (2002) Elevated
nucleoplasmic glycosylation by O-GlcNAc results in insulin
resistance associated with defects in Akt activation in 3T3–L1
adipocytes. Proc Natl Acad Sci USA 99:5313–5318
31. Robinson KA, Ball LE, Buse MG (2007) Reduction of O-
GlcNAc protein modification does not prevent insulin resistance
in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 292:
E884–E890
32. Di Jeso B, Ulianich L, Pacifico F et al (2003) Folding of
thyroglobulin in the calnexin/calreticulin pathway and its alter-
ation by loss of Ca2+ from the endoplasmic reticulum. Biochem J
370:449–458
33. Di Jeso B, Pereira R, Consiglio E, Formisano S, Satrustegui J,
Sandoval IV (1998) Demonstration of a Ca2+ requirement for
thyroglobulin dimerization and export to the Golgi complex. Eur J
Biochem 252:583–590
34. Pirot P, Naamane N, Libert F et al (2007) Global profiling of
genes modified by endoplasmic reticulum stress in pancreatic beta
cells reveals the early degradation of insulin mRNAs. Diabetolo-
gia 50:1006–1014
35. Harding H, Zhang Y, Ron D (1999) Translation and protein
folding are coupled by an endoplasmic reticulum resident kinase.
Nature 397:271–274
36. Lawrence MC, McGlynn K, Park BH, Cobb MH (2005) ERK1/2-
dependent activation of transcription factors required for acute and
chronic effects of glucose on the insulin gene promoter. J Biol
Chem 280:26751–26759
37. Ohneda K, Ee H, German M (2000) Regulation of insulin gene
transcription. Semin Cell Dev Biol 11:227–233
38. Frayling TM, Evans JC, Bulman MP (2001) Beta cell genes and
diabetes: molecular and clinical characterization of mutations in
transcription factors. Diabetes 1:S94–S100
39. Olbrot M, Rud J, Moss LG, Sharma A (2002) Identification
of beta cell-specific insulin gene transcription factor RIPE3b1
as mammalian MafA. Proc Natl Acad Sci USA 99:6737–
6742
40. Lu M, Seufert J, Habener JF (1997) Pancreatic beta cell-
specific repression of insulin gene transcription by CCAAT/
enhancer-binding protein beta. Inhibitory interactions with
basic helix–loop–helix transcription factor E47. J Biol Chem
272:28349–28359
41. Inagaki N, Maekawa T, Sudo T, Ishii S, Seino Y, Imura H (1992)
c-Jun represses the human insulin promoter activity that depends
on multiple cAMP response elements. Proc Natl Acad Sci USA
89:1045–1049
42. Khoo S, Cobb MH (1997) Activation of mitogen-activating
protein kinase by glucose is not required for insulin secretion.
Proc Natl Acad Sci USA 94:5599–5604
43. Briaud I, Lingohr MK, Dickson LM, Wrede CE, Rhodes CJ
(2003) Differential activation mechanisms of Erk-1/2 and p70
(S6K) by glucose in pancreatic beta-cells. Diabetes 52:974–
983
44. Arnette D, Gibson TB, Lawrence MC et al (2003) Regulation of
ERK1 and ERK2 by glucose and peptide hormones in pancreatic
beta cells. J Biol Chem 278:32517–32525
45. Dougherty MK, Ritt DA, Zhou M et al (2009) KSR2 is a
calcineurin substrate that promotes ERK cascade activation in
response to calcium signals. Mol Cell 34:652–662
Diabetologia
46. Khaldi MZ, Guiot Y, Gilon P, Henquin JC, Jonas JC (2004)
Increased glucose sensitivity of both triggering and amplifying
pathways of insulin secretion in rat islets cultured for 1 wk in high
glucose. Am J Physiol Endocrinol Metab 287:E207–E217
47. Piwien-Pilipuk G, Galigniana MD, Schwartz J (2003) Subnuclear
localization of C/EBP is regulated by growth hormone and
dependent on MAPK. J Biol Chem 278:35668–35677
48. Yang TT, Xiong Q, Graef IA, Crabtree GR, Chow CW (2005)
Recruitment of the extracellular signal-regulated kinase/ribosomal
S6 kinase signaling pathway to the NFATc4 transcription
activation complex. Mol Cell Biol 25:907–920
49. Khoo S, Griffen SC, Xia Y, Baer RJ, German MS, Cobb MH
(2003) Regulation of insulin gene transcription by extracellular-
signal regulated protein kinases (ERK) 1 and 2 in pancreatic beta
cells. J Biol Chem 278:32969–32977
50. Rutkowski DT, Hegde RS (2010) Regulation of basal cellular
physiology by the homeostatic unfolded protein response. J Cell
Biol 189:783–794
Diabetologia
1 
Francesco Beguinot and Cecilia Nigro 
 
Dipartimento di Biologia e Patologia Cellulare e Molecolare & Istituto di 
Endocrinologia ed Oncologia Sperimentale del CNR – Federico II University of 
Naples, Italy 
 
Corresponding author: beguino@unina.it 
 
Title:   Measurement of Glucose Homeostasis in vivo: Glucose 
and  
   Insulin Tolerance Tests 
 
Running title:  Glucose and insulin tolerance tests  
 
Summary 
 
The feasibility of investigating glucose tolerance and insulin action and secretion in 
vivo  in mouse models has provided major insights into both type 2 diabetes 
pathogenesis and the identification of novel strategies to treat this common 
disorder. When initial studies provide evidence for altered levels of insulin and/or 
glucose in the animal blood, a number of well-characterized tests can be adopted 
to estimate glucose homeostasis, insulin action and secretion in vivo. These tests 
include model assessments, glucose and insulin sensitivity studies and glucose 
clamps. None of them can be considered appropriate under all circumstances and 
there is significant variation in their complexity, technical ease and invasiveness. 
Thus, while the euglycaemic hyperinsulinemic clamp represents the gold standard 
for measuring in vivo insulin action, less labour-intensive as well as invasive 
techinques are usually considered as the initial approach to evaluate glucose 
homeostasis. This section will focus on glucose and insulin tolerance tests. The 
clamp technique is described in section 2b. 
 
Keywords: Type 2 diabetes, insulin resistance, insulin sensitivity, mouse 
phenotyping, insulin secretion. 
 
1. Introduction 
Insulin represents the major regulator of glucose homeostasis (1). The post-
prandial rise in plasma insulin enables appropriate disposal of blood glucose in the 
absorptive state, while the fall in plasma insulin contributes to maintaining 
euglycaemia in the post-absorptive state and during starvation (2). In all mammals, 
these normal fluctuations in insulin levels are dependent upon the ability of 
pancreatic beta-cells to respond to changes in plasma glucose levels by 
modulating insulin secretion (3). 
 
Type 2 diabetes is the most common abnormality of glucose homeostasis and the 
most frequent endocrine disorder (4). Current evidence indicates that, in the years 
preceeding type 2 diabetes onset, a progressive deterioration of insulin sensitivity 
in liver and peripheral tissues and of beta-cell insulin secretion occurs (Fig.1). This 
leads to increasingly abnormal glucose tolerance and, finally, to type 2 diabetes 
(5). How these abnormalities are generated and become established remain 
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ultimately unclear, but tremendous interest to solve this problem has accumulated 
also due to the epidemic diffusion of type 2 diabetes. This circumstance has 
strengthened the motivation to adopt the convenient mouse model for dissecting 
the genetic and the molecular causes of type 2 diabetes. 
 
In mice as in humans, derangement in glucose homeostasis is often suspected on 
the bases of elevated plasma insulin or glucose levels. These abnormalities can 
be further investigated in the mouse by methodologies similar to those commonly 
used in humans, including measurements of fasting and post-load glucose and 
insulin levels, glucose and insulin sensitivity tests and the more invasive clamps 
(TABLE I). These different approaches correlate quite well and may enable both 
an accurate characterization of glucose tolerance, i.e., the ability to rescue basal 
glycaemia upon a load, and identification of major reasons for derangement in 
glucose homeostasis. 
 
An important and general consideration when assessing glucose tolerance, 
plasma insulin or glucose concentrations in mice (as well as in humans) is that the 
conditions under which these variables are measured must be carefully taken into 
account, as they are affected by a number of physiological and environmental 
factors in addition to pathological situations. These include physical activity levels, 
the time of the day and stress. For example, stress-induced increase in 
catecholamines and cortisol levels can enhance liver glucose production and 
affect the assessment of glucose tolerance (6). Also, mice usually exhibit higher 
cortisol levels in the evening, leading to increased glucose production. Finally, as 
for many other tests used in the endocrinological assessment of the mouse 
phenotype, the validity of results obtained is largely dependent on methods of 
animal husbandry. Adequate experience of the personnel performing the tests is 
key to reduce the anxietly levels of the mice both before and during the 
experiments. Reference values for metabolite and hormone levels in many mouse 
strains are available through the Jackson Laboratories web site 
(http://www.jacksonlaboratory.com). 
 
2. Material 
2.1 Detection of blood glucose concentrations 
1. Blood glucose monitor and associated test strips for glucose measurement 
(e.g., Accu-Check Active, Roche Diagnostics). 
2. Low and high-level glucose control solutions (e.g., Accu-Check Active glucose 
control solutions, Roche Diagnostics; low concentration: 50 mg/dL, reference 
range 42 to 72 mg/dL, and high concentration: 300 mg/dL, reference range 
290 to 328 mg/dL). 
3. Scalpel blade. 
 
2.2 Detection of insulin concentration 
1. Mouse serum or plasma. 
2. Microtiter plate shaker. 
3. Microtiter plate washer. 
4. Plate reader with 450 nm reading capability. 
5. Ultrasensitive Mouse Insulin ELISA kit (e.g. Mercodia). 
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2.3 Oral glucose tolerance test 
1. 20% (w/v) aqueous glucose solution. 
2. Animal scale. 
3. Blood glucose monitor and test strips for glucose measurement (e.g. Accu-
Check Active, Roche Diagnostics). 
4. Scalpel blade. 
5. 1-mL syringe (e.g. Terumo) and 22-G ball-tip needle (e.g. Popper and Sons). 
6. Timer. 
 
2.4 Intraperitoneal insulin tolerance test 
1. Animal scale. 
2. Blood glucose monitor and test strips for glucose measurement (e.g. Accu-
Check Active, Roche Diagnostics). 
3. Fast-acting insulin solution. 
4. Scalpel blade. 
5. 1-mL syringe (e.g. Terumo) and 25-G x 5/8-in. Needles (e.g. Terumo). 
6. Timer. 
 
4. Methods 
4.1 Determination of glycaemia by glucose monitor 
Blood glucose concentration is often the first parameter to be determined when 
defining the metabolic phenotype, as abnormalities are indicative of alterations in 
glucose homeostasis. Blood glucose can be assayed on plasma or serum 
samples, which is usually achieved by enzymatic methods using either hexokinase 
or glucose oxidase. Whether performed manually or authomatically, this approach 
is specially useful when samples are to be frozen and/or analyzed at a later point 
in time. Alternatively, glucose concentration can be conveniently determined on 
whole blood using the portable glucose monitors designed for human diabetes 
self-control. These devices are inexpensive, easy to use and provide fast and 
reliable results from very small volumes of blood. The protocol below describes the 
use of the Accu-Chek Active blood glucose monitor from Roche Diagnostics. Other 
widely used monitors include the HemoCue Glucose (HemoCue), BD Logic Blood 
Glucose Monitor (BD), Precision Xtra (Abbott) and One Touch Ultra (LifeScan). 
1. Calibrate the blood glucose monitor as described in the manufacturer’s user 
manual of the device, and repeat calibration each time a new box of test strips 
is used (see Note 1). 
2. Using the low and the high-level glucose control solutions, execute a 
performance check on the monitor as described in the manufacturer’s user 
manual of the device. This routine should be repeated each time a new box of 
test strips is used, or if uncertain of the monitor performance. Use the same lot 
of test strips for one experiment as intra-lot variations can occur (see Note 1). 
3. Insert a new test strip in the device. 
4. Draw an approximately 3 L blood drop from a mouse by notching the lateral 
tail vein 1-2 cm from the tip using a scalpel blade and apply the drop to the test 
strip by touching the strip directly to the bleeding tail wound. 
5. Read and record the test result (see Note 2). 
6. Facilitate blood clotting by applying gentle mechanical pressure to the tail 
wound and return the mouse in its cage. 
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3.2 Determination of insulinemia by ELISA 
For measuring the plasma insulin concentration we recommend the use of the 
Ultrasensitive Mouse Insulin ELISA by Mecordia. The assay is based on a solid-
phase direct sandwich ELISA and adopts two monoclonal antibodies against 
separate epitopes of the insulin molecule. Sample insulin is immobilized by the 
first antibody bound to the assay well, followed by labelling with peroxidase-
conjugated antibodies. The bound insulin is then revealed colorimetrically. Other 
commercially available ELISA kits for measuring insulin in small volumes include 
the Linko Research kit. 
1. Pipet calibrator 0 (25 L) into each well of a 96-well microtiter plate coated with 
mouse insulin antibody. 
2. Pipet calibrators (5 L) and mouse serum or plasma (5 L) into duplicate wells 
of the antibody-coated microtiter plate (see Note 3). 
3. Add 50 L of antibody-enzyme conjugate reagent to each well (the reagent is 
prepared by diluting the concentrated antibody-enzyme conjugate provided 
with the commercial kit as specified in the manufacturer’s instructions. 
4. Incubate on a shaker for 2h at room temperature (18° – 25°C). 
5. Aspirate the reaction volume, add 350 L of wash buffer to each well and 
aspirate completely. Repeat this procedure five more times. The wash buffer is 
prepared by diluting the concentrated wash buffer provided with the 
commercial kit as specified in the kit manufacturer’s instructions). 
6. After the last wash, invert the plate and tap firmly against absorbent paper. 
7. Add 200 L of TMB substrate reagent (provided with the kit) to each well (light-
sensitive reagent). 
8. Incubate 30 min at room temperature. 
9. Add 50 L stop solution. 
10. Place the plate on the shaker for about 10 sec to enable adequate mixing of 
substrate and stop reagents. 
11. Measure the absorbance at 450 nm and compute results according to the kit 
manufacturer’s instructions (for manual calculation, plot the calibrators on a 
log-log or log-in paper and read the insulin concentrations for each sample 
from the curve). 
12. If the insulin concentration exceeds the value of the highest calibrator, dilute 
the sample ten-fold with 0.9% NaCl and repeat the analysis. 
 
3.3 Oral glucose tolerance test 
The oral glucose tolerance test (OGTT) enables an estimate of the clearance of a 
standard bolus of glucose. At variance from the intraperitoneal glucose tolerance 
test (IPGTT) described in 3.4, the OGTT is based on orally administered glucose, 
so that its clearance is also determined by intestinal factors. Animals tested by 
OGTT are starved for 14-16 h, followed by glucose administration by gavage and 
blood or plasma glucose measurement through the following 3h. The oral gavage 
techniques is fully described in (7). In each experimental setting, two trained 
persons should cooperate with one of them only performing the gavage in the 
entire group of animals. In order to achieve interpretable results, it is advisable that 
no more than 16 mice are treated in each experimental setting. Accordingly, 
accurate experimental design to divide the animal group is necessary. 
1. Fast mice for 14-16 h (overnight) with constant access to drinking water. 
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2. On the following day, at 8:00 A.M., place each mouse in a fresh cage with 
access to water and identify each cage with the mouse number. 
3. Record the weight  of each mouse. 
4. Calculate and record the volume of the 20% glucose solution required for oral 
gavaging of 2g of glucose/kg (oral injection volume 10 L/g body weight). 
5. Prepare strips for glucose measurements, record sheets, and a 1mL syringe 
for each animal containing the calculated glucose to be gavaged. One ball-tip 
needle can be used through the entire experiment, switching it between the 
different syringes upon fast external rinsing with 70% ethanol and water. 
6. Calibrate the blood glucose monitor as described in 3.1. 
7. Determine the basal glucose concentration in each mouse (T0) by removing 
one mouse at a time, placing it on the top of its cage and drawing blood from 
the lateral vein of the tail as previously outlined in 3.1. Place the blood sample 
on the test strip of the glucose monitor, read and record the result. Facilitate 
blood clotting on the tail incision as previously described and return the mouse 
in its cage. 
8. After the basal glucose concentrations has been determined in all mice, 
perform gavaging and administer the glucose load to each mouse, maintaining 
a 30-60 sec interval between animals, depending on the size of the 
experimental group. Start the timer upon the first mouse has been gavaged. It 
takes at least 30 seconds for an experienced investigator to perform gavaging 
and blood glucose determination (see Note 4). 
9. At T15, measure  the blood glucose again, starting with the first mouse 
gavaged and maintaining the same time interval until all of the mice in the 
experimental group have been assesed. To enable rebleeding, remove the 
clot from the incision and massage the tail as needed to enable sufficient 
blood flow. 
10. Repeat this procedure at T30, T60, T90, T120, T150, T180 (see Note 5). 
11. At the end of the experiment, return mice in their original cages and make sure 
that none of them is beeding. Also, make sure that animals food and drinking 
water is available again. 
12. Data are usually plotted as glucose values versus time. Statistical treatment of 
the data can be simplified by calculating, for each mouse, areas under the 
curves as in (8). 
 
3.4 Intraperitoneal glucose tolerance test 
The intraperitoneal glucose tolerance test (IPGTT) measures the clearance of an 
intraperitoneally-injected glucose load by tissues. Compared to the OGTT, IPGTT 
does not address the intestinal phase of glucose absorption and is, therefore, a 
less physiological test. The procedure is very similar to that used for OGTT with 
the exception that the glucose load is injected intraperitoneally rather than by 
gavaging (see Note 6). Accordingly, matherials and methods will not be outlined 
again. Please refer to 3.3 for details (see Note 7). Same as for oral administration, 
a 2g glucose/kg load should be used, with an intraperitoneal injection volume of 
10L/g body weight. The same considerations on timing and group size apply to 
IPGTT and to OGTT (see 3.3). 
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3.5 Intraperioneal insulin tolerance test 
The intraperitoneal insulin tolerance test (IPITT) measures glucose levels upon 
administration of a standard insulin bolus, providing an estimate of the insulin 
sensitivity of the animal. Animals are fasted for 14 to 16 h and subjected to 
intraperitoneal insulin loading. Blood glucose levels are measured at different time 
points through the following 90 min. 
As for glucose tolerance studies, experimental design of IPITT studies must take 
into serious consideration the size of the experimental sample. Again, it is 
advisable that no more than sixteen animals are examined during the same 
experimental set-up with two trained personnel units each of which is attributed 
specific roles in the experiment. To minimize technical variation, insulin should be 
injected by the same unit of personnel to all of the mice. 
1. Fast mice for 14-16 h (overnight) with constant access to drinking water. 
2. On the following day, at 8:00 A.M., place each mouse in a fresh cage with 
access to water and identify each cage with the mouse number. 
3. Record the weight  of each mouse. 
4. Calculate and record the volume of insulin solution required for an 
intraperitoneal injection of 0.5 IU/kg in an injection volume of 3.6 L/g body 
weight. 
5. Prepare the 1 mL insulin syringes and 25-G x 5/8-in. needles with the 
calculated volumes for each animal in the experiment. Prepare experiment 
record sheets and test strips for glucose measurement (see Note 8). 
6. Calibrate the glucose monitor with the standard strip. 
7. Determine the basal glucose levels in each mouse by removing one mouse at 
a time from its cage, placing it on the top of the cage and drowing blood from 
the lateral vein of the tail as outlined in 3.1. Facilitate blood cloting as 
described under in 3.1. 
8. Inject insulin intraperitoneally in each mouse at 30-60 sec interval between 
animals, depending on the size of the experimetal group. Start the timer when 
the first mouse is injected (see Note 9). 
9. At T15, determine blood glucose again, starting with the first mouse injected 
and using the same interval adopted for injection, until all the mice in the 
experimental group have been measured. To restart bleeding, gently remove 
the clot from the incision and massage the tail as needed to increase the blood 
flow. 
10. Repeat the above sequence at T30, T60 and T90 after insulin injection. If at any 
time during implementation of the protocol, blood glucose falls below 36 
mg/dL, the value must be confirmed. If confirmed, the mouse must be rescued  
by injecting 0.5-1.0 g glucose/kg from a 20% glucose solution as 
hypoglycaemia might be otherwise lethal (see Note 10). 
11. Data are usually presented by plotting glucose values versus time. If mice 
significantly differ in their basal glucose levels, plotting % of basal value versus 
time may represent a valid alternative. 
12. Calculation of areas under the curve may provide additional information, 
especially if the initial and the late phases (the last 90-60 min, when 
counterregulatory hormones start playing a major role) are analyzed 
separately. 
 
 
7 
4. Notes 
1. The small size of the blood volume of a normal mouse requires high 
sensitivity of all of the procedures adopted to assay circulating metabolites. 
This requirement is particularly strict in the case of glucose as the 
accomplishment of several metabolic tests needs repeated sampling over 
short periods of time.  
2. For very low (<2mM) or very high glucose levels (reported upper limit for the 
Accu-Check monitor is 33.3 mM) use of alternative methods to confirm 
readings is highly advisable. 
3. Fasting insulin levels in many mouse strains are close to the sensitivity limit 
of most commercially available kits (0.2 g/L for the Mercodia kit). Attention 
must be payed to the storage conditions of the serum /plasma samples and 
their freeze-thaw cycles. Also, the upper level detection limits of many 
commercial kits (7 g/L for the Mercodia kit) are relatively low compared to 
the insulin levels which may be achieved in certain experimental conditions. 
This circumstance may require adequate dilution of the samples and re-test. 
4. Correct oral gavaging is essential and must be performed by experienced 
personnel to avoid tracheal instead of oesophagus gavaging.  
5. After the load (T15), blood glucose is expected to increase 1.5 to 2-fold, 
followed by a slow return toward the basal values. However, in insulin-
resistant states, peak glucose concentration is usually higher and return to 
basal slower. The kinetics of blood glucose excursion resembles that 
occurring during IPGTT, although glucose peak is usually reached later, it is 
somewhat more blunted and the return toward the basal condition is slower. 
During all tolerance tests, changes in glucose and insulin levels are 
dynamic. Therefore, the number of animals used in each experimental group 
must be small enough to precisely respect of the scheduled timetable, 
perticularly during the initial phases of the study where the most rapid 
changes occurs (tipically the T0 to T30 in the glucose tolerance tests). 
6. An important technical concern, specially with obese mice, is that the 
glucose solution may end up to be injected in the adipose depots, slowing 
absorption. This circumstance may offer reasons for even greater concern 
when animals with large difference in the amount of fat tissue are compared. 
Since direct possibilities to clarify this issue are scarce, efforts must be 
devoted at the time of data analysis to identify unresponsive animals. 
7. Initial glucose peaks during IPGTT should be at least 2-fold higher than 
baseline levels but can be even 10-fold higher depending on the particular 
experimental set-up, including the mouse genetic background. When insulin 
is measured in addition to glucose, values usually follow the changes in 
glycaemia. On the other hand, a significant increase in peak glucose (T0-T30) 
may be indicative of defective beta-cell function. 
8. For some mouse strains, the insulin dose recommended in the above 
protocol may be too high and result in severe, even lethal hypoglycaemia. 
Since this circumstance is somewhat impredictable, it is advisable that a 
preliminary test with a small number of mice is implemented to assess the 
insulin sensitivity of the particular mouse strain unders study. From a 
practical perspective it is also advisable that only freshly prepared insulin 
solutions are used, as this will prevent excessive binding to the test tube 
walls and the syringe. 
8 
9. As in the case of IPGTT, adiposity may create reasons for concern when 
data from IPITT are to be analyzed, specially if study groups differ 
significantly for abdominal fat (see under Protocol 4). 
10. Upon insulin injection, blood glucose typically falls from the basal levels until 
T30, after which it tends to stabilize and slowly returns toward basal levels. 
Slower recovery from hypoglycaemia may indicate failure of the counter-
regulatory system and or impaired glucose production. 
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Table 1 
Basic methods used to assess insulin sensitiviy and glucose tolerance1 
 
Test Sample Method 
FPG and FPI One 50 L blood sample  Overnight or 4h fasting 
glucose and insulin 
measurements 
OGTT Eight 3 L blood samples Overnight fast and 
glucose measurement 
after oral glucose load 
IPGTT Eight 3 L blood samples Overnight fast and 
glucose measurements 
after I.P. glucose load 
IPITT Six 3 L blood samples Overnight fast and 
glucose measurements 
after I.P. glucose load 
 
FPG, fasting plasma glucose; FPI, fasting plasma insulin; OGTT, oral glucose 
tolerance test; IPGTT, intaperitoneal glucose tolerance test; IPITT, intraperitoneal 
insulin tolerance test; I.P., intraperitoneal. 
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Abstract
Aims/hypothesis Overexpression of PED (also known as
PEA15) determines insulin resistance and impaired insulin
secretion and may contribute to progression toward type 2
diabetes. Recently, we found that the transcription factor
hepatocyte nuclear factor (HNF)-4α binds to PED promoter
and represses its transcription. However, the molecular
details responsible for regulation of PED gene remain
unclear.
Methods Here we used gain and loss of function
approaches to investigate the hypothesis that HNF-4α
controls chromatin remodelling at the PED promoter in
human cell lines.
Results HNF-4α production and binding induce chroma-
tin remodelling at the −250 to 50 region of PED,
indicating that remodelling is limited to two nucleosomes
located at the proximal promoter. Chromatin immunopre-
cipitation assays also revealed concomitant HNF-4α-
induced deacetylation of histone H3 at Lys9 and Lys14,
and increased dimethylation of histone H3 at Lys9. The
latter was followed by reduction of histone H3 Lys4
dimethylation. HNF-4α was also shown to target the
histone deacetylase complex associated with silencing
mediator of retinoic acid and thyroid hormone receptor,
both at the PED promoter, and at GRB14 and USP21
regulatory regions, leading to a reduction of mRNA levels.
Moreover, HNF-4α silencing and PED overexpression
were accompanied by a significant reduction of hepatic
glycogen content.
Conclusions/interpretation These results show that HNF-4α
serves as a scaffold protein for histone deacetylase activities,
thereby inhibiting liver expression of genes including
PED. Dysregulation of these mechanisms may lead to
upregulation of the PED gene in type 2 diabetes.
Keywords Chromatin remodelling . HNF-4α . Insulin
resistance . PED . Type 2 diabetes
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H3K4 Histone H3 Lys4
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panSMRT Regions common to SMRTα and
SMRTβ
PED Phosphoprotein enriched in diabetes
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siRNA Short interfering RNA
SMRT Silencing mediator of retinoic acid and
thyroid hormone receptor
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Introduction
Recent genetic studies [1–3] have considerably expanded
the list of known genes that may cause a predisposition to
diabetes. However, it remains largely unclear how these
genes determine the development of type 2 diabetes.
Phosphoprotein enriched in diabetes (PED, also known as
phosphoprotein enriched in astrocytes-15 [PEA15]) is a
scaffold cytosolic protein widely produced in human tissues
[4, 5]. Early studies indicated that PED has an important
role in controlling glucose disposal by impacting on protein
kinase C signalling [5, 6]. It was later found that PED is
commonly overproduced in individuals with type 2 diabetes
as well as in their euglycaemic offspring [5, 7]. In these
persons PED overproduction causes insulin resistance in
GLUT4-mediated glucose disposal. Studies in tissue-
specific transgenics and in null mice have indicated that
the upregulation of PED observed in type 2 diabetic
patients might also contribute to impaired beta cell function
[7]. PED cellular levels are regulated by ubiquitinylation
and proteosomal degradation [8], but run-on experiments in
cultured cells from type 2 diabetic patients have demon-
strated that, at least in part, the overproduction observed in
these participants is caused by transcriptional abnormalities
[5]. The molecular details responsible for these abnormal-
ities and how the PED gene is regulated remain unclear.
Moreover, the role of PED in liver glucose metabolism has
been less extensively investigated.
We have recently demonstrated that the hepatocyte
nuclear factor (HNF)-4α (NR2A1), a highly conserved
member of the nuclear receptor superfamily involved in the
control of glucose homeostasis [9, 10], regulates transcrip-
tion of the PED gene by binding to a cis-regulatory element
of the PED promoter and represses its transcription [11].
HNF-4α is essential for hepatocyte differentiation at the
developmental and the functional levels [12], as well as for
accumulation of hepatic glycogen stores and generation of
normal hepatic epithelium [13]. Point mutations in HNF-4α
impair liver and pancreatic regulation of glucose homeo-
stasis and cause maturity onset diabetes of the young type 1.
More recently, genetic and biochemical evidence has been
generated indicating that HNF-4αmay also have a role in the
development of more common forms of type 2 diabetes
[14–16], but understanding of the underlying mechanisms
is incomplete.
The ability of nuclear receptors to induce specific
transcription events depends on their recruitment of
chromatin remodelling cofactors and enzymes, and on the
assembly of the basal transcription machinery [17]. In the
absence of ligand, nuclear receptors recruit co-repressors
such as silencing mediator of retinoic acid and thyroid
hormone receptor (SMRT) and nuclear receptor co-
repressor. These, in turn, bind repressive enzymes such as
the histone deacetylases and histone methyltransferases,
specifically controlling the methylation state of lysine 9 at
histone H3 and certain chromatin remodelling events.
Increasing evidence now indicates that chromatin
remodelling is an important mechanism enabling transcrip-
tion regulation [18]. Chromatin remodelling occurs through
different mechanisms. One is the covalent modification of
histone tails, including acetylation, methylation and phos-
phorylation [19]. These changes also affect the ability of
chromatin to interact with transcription factors and the basal
transcription machinery [20]. Acetylation and methylation
of lysine residues at H3 and H4 amino termini represent the
most common modifications. Indeed, increased acetylation
induces transcriptional activation [21], while reduced
acetylation usually signals transcriptional repression [22,
23]. Methylation of H3 lysine 9 is also associated with
transcriptional repression [24].
In this work, we have investigated the molecular
mechanisms responsible for HNF-4α-dependent silencing
of PED expression in liver. We show that by causing
epigenetic changes at the PED gene, HNF-4α controls
transcriptional activity of PED and may affect glucose
metabolism in liver.
Methods
Materials Media, sera and antibiotics for cell culture, and
the lipofectamine reagent were purchased from Invitrogen
(Paisley, UK). Goat polyclonal HNF-4α and acetyl-histone
H3 (K9/K14) and rabbit polyclonal SMRTe antibodies were
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Mouse monoclonal histone H3 Lys9 (H3K9) and rabbit
monoclonal histone H3 Lys4 (H3K4) antibodies were from
Abcam (Cambridge, UK). The PED antibody, the
pCDNA3/HNF-4α expression vector and the HNF-4α-
specific short hairpin RNA (shRNA) plasmid have been
previously described [11]. All short interfering RNAs
(siRNAs) were chemically synthesised by Ambion (Austin,
TX, USA) as oligonucleotide duplexes. siRNA target
sequences for silencing mediator for retinoid and thyroid
hormone receptors (SMRT) were directed at regions
common to SMRTα and SMRTβ (panSMRT) [25]. As
non-specific siRNA controls, the Ambion Silencer 2
negative control was used.
Western blot and electrochemiluminescence (ECL) reagents
were from Thermo Scientific (Rockford, Illinois, USA). All
other reagents were from Sigma (St Louis, MO, USA).
Animal studies, cell culture, transfections, RT-PCR and
western blot assay The PED transgenic mice and cellular
models generation have been previously described [11, 26].
Total RNA extraction, cDNA synthesis, real-time PCR and
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western blot analysis were performed as described in [11].
Antibodies against SMRT, HNF-4α, PED and actin were
used for detection of proteins. All the experiments
involving animals were approved by the Local Ethics
Committee and conducted in accordance with the Principles
of Laboratory Care.
Formaldehyde-assisted isolation of regulatory ele-
ments Whole cells were fixed in growth medium by
addition of 37% (vol./vol.) formaldehyde to a final
concentration of 1% (vol./vol.) formaldehyde for 10 min.
The fixed cells were resuspended in nuclear lysis buffer
containing 50 mmol/l Tris–HCl (pH 8.0), 10 mmol/l EDTA,
0.8% (wt/vol.) sodium dodecyl sulphate, 1 mmol/l phenyl
methyl sulfonyl fluoride and inhibitors cocktail (Sigma),
and then incubated on ice for 10 min. The extracts were
then sonicated (Misonix 3000) and microcentrifuged for
10 min at 16,000 g and 4°C. Protein-free DNA was then
analysed by SYBR Green real-time PCR [27]. The primer
sets used are shown in Electronic supplementary material
(ESM) Table 1. The amount of PCR product (representing
nucleosome-free DNA) was plotted as a percentage of the
input DNA representing total cellular DNA.
Micrococcal nuclease protection assay Nuclei were isolated
from 1×108 of the following cells: HeLa wild-type, HeLa
overproducing exogenous HNF-4α (HeLaHNF‐4a) HepG2
and HepG2 subjected to silencing of the endogenous
HNF-4α (HepG2HNF‐4a‐sh). Isolated nuclei were suspended
in 1 ml of wash buffer (10 mmol/l Tris–HCl, pH 7.4,
15 mmol/l NaCl, 50 mmol/l KCl, 0.15 mmol/l spermine,
0.5 mmol/l spermidine and 8.5% [wt/vol.] sucrose) and
digested with 120 U of micrococcal nuclease (MNase) for
30 min at 37°C. The purified DNA was quantified and
identified on an agarose gel, and subsequently amplified by
PCR using the C, D and F primer sets. An aliquot of
undigested DNAwas obtained as a control of total cellular
DNA quality.
Chromatin immunoprecipitation and re-chromatin immuno-
precipitation assay procedures Chromatin immunoprecipi-
tation (ChIP) assay was performed as previously described
[11]. Sheared chromatin samples were taken as input
control or used for immunoprecipitation with the following
antibodies: acetyl-histone H3 (sc-8655), dimethylated
histone H3 at lysine 9 (H3K9me2; ab-1220), H3K4me2
(ab-7766), HNF-4α (sc-6556), SMRTe (sc-1612) and
normal rabbit IgG as a negative control. DNA fragments
were recovered and subjected to real-time PCR amplifica-
tion using primer sequences described in Table 1.
For re-chromatin immunoprecipitation (Re-ChIP) assay,
immunoprecipitates with the first antibody were eluted in
50 µl of dithiothreitol 10 mmol/l, diluted tenfold in ChIP
dilution buffer supplemented with protease inhibitors and
immunoprecipitated with the second antibody. Following
immunoprecipitation, samples were processed as described
for ChIP assay [11] and eluted DNAwas amplified by real-
time PCR with specific oligos.
Trichostatin A treatment of cells HepG2 cells were seeded
in 10 cm dishes at a density of 1×106 cells 1 day before drug
treatment. The cells were treated with 330 nmol/l trichosta-
tin A (Sigma-) for 1 day, and total RNA and chromatin
were prepared as described before.
Hepatic glycogen measurement Cells and tissues were
solubilised in 0.1% (wt/vol.) sodium dodecyl sulphate
and then further incubated with 1:1 saturated Na2SO4 and
95% (vol./vol.) ethanol. The pellets were rehydrated, and
5% (vol./vol.) phenol and H2SO4 were added. Finally,
absorbance at 490 nm was measured. Results are expressed
as micrograms of glycogen per milligram of protein or
tissues.
Statistical procedures Statistical analysis was performed
with a software package (StatView 5.0; Abacus Concepts,
Berkley, CA, USA) using the Student’s t test. Values of
p<0.05 were considered statistically significant.
Results
HNF-4α induces DNA remodelling and nucleosome posi-
tioning at the PED promoter As previously reported, HeLa
cells feature high expression of the PED gene, while very
low expression was found in the HepG2 cells [11].
Expression of the PED silencer HNF-4α is inversely
related to that of PED in these cells [11]. Thus, these cell
lines represent an attractive model to investigate the
molecular mechanisms responsible for HNF-4α regulation
of PED gene transcription. To investigate changes induced
by HNF-4α in chromatin structure across the PED
promoter, we isolated nucleosome-free chromatin DNA
from HeLa cells (either wild-type or expressing an HNF-4α
[also known as HNF4A] cDNA) and from HepG2 cells
(wild-type and expressing an HNF-4α shRNA) by
performing a formaldehyde-assisted isolation of regulatory
elements assay [28]. The DNA fragments were amplified
using seven sets of PCR primers, covering consecutive
100 bp regions positioned at −500 to 300 in the PED gene
(Fig. 1a, ESM Table 1) and PCR amplification was
monitored by SYBR green incorporation [29]. The amount
of DNA amplified (nucleosome-free DNA) was plotted as
percentage of the input DNA representing total cellular
DNA.
1484 Diabetologia (2010) 53:1482–1492
In HeLaHNF‐4a, the amount of nucleosome-free DNA
across the examined regions ranged from 25 to 65%
compared with untransfected HeLa cells showing higher
free DNA amounts (Fig. 1b). HepG2HNF‐4a‐sh featured high
levels and low reduction of nucleosome-free DNA, com-
pared with untransfected HepG2 cells exhibiting high
expression levels of HNF-4α and reduced free DNA across
the −500 to 300 region of the PED gene (Fig. 1c). In
HeLaHNF‐4a and HepG2 cells, three regions were found to
be associated with reduced levels of free DNA. These
corresponded to the HNF-4α response element (HRE; at
−350, region B), its immediate proximity (−200, region C)
and the proximity of the PED transcription start site (−50,
region D).
To further investigate nucleosome positioning across the
PED promoter, mononucleosomal DNA averaging 150 bp
in size was obtained by nuclear MNase digestion of HeLa
cells (either transfected with HNF-4α or untransfected) and
HepG2 cells (transfected with HNF-4α-sh or untransfected;
Fig. 2a). This DNA was subsequently amplified using the
PCR primer sets for the C and D regions shown in Fig. 1b.
Figure 2b shows the results obtained with primer set C;
similar results were obtained with primer set D (data not
shown). In agarose gel electrophoresis, the amplification
products were barely detectable when using the mono-
nucleosomal DNA from HeLa cells, but were signifi-
cantly increased with the DNA from the HeLaHNF‐4a cells
(C region). Consistently, only a weak band was obtained
in HNF-4α-silenced (HepG2HNF‐4a‐sh) cells compared with
the untransfected HepG2 cells (C region). The use of
undigested DNA in control PCR assays led to the
amplification of a 120 bp band with all of the cell lines
(C region). Also, upon MNase treatment, the nucleosome-
free exon 2 allowed no PCR amplification with F region
primers (Fig. 2c), although clear amplification bands were
obtained with the undigested DNA (F region). These data
Fig. 2 Accessibility of PED gene regions to MNase digestion. HeLa,
HeLaHNF‐4a , HepG2 and HepG2HNF‐4a‐sh nuclei were digested with
120 U of MNase for 30 min, which extensively digests the linker and
nucleosome-free regions. a Representative image of digested nucleo-
somes separated on a 2% agarose gel before purification. First lane
contains a DNA marker ladder. The arrow indicates mononucleo-
somes. b PCR amplification with primer sets from Fig. 1a as indicated
using mononucleosomal DNA (bottom rows) and genomic DNA as
positive control (top rows) for C region and (c) F region. The PCR
products are shown for each primer set after agarose gel electropho-
resis. Photographs are representative of three (a) and four (b, c)
independent experiments
Fig. 1 Enrichment of regulatory DNA across 0.8 kb of PED gene
using formaldehyde-assisted isolation of regulatory elements.
a Schematic representation of PED showing the HRE, the transcrip-
tion start site, the exon 2 position and the DNA fragments amplified
by primer sets A to F. b Protein-free DNA was extracted from HeLa
(black bars) and HeLaHNF‐4a (grey bars), and (c) from HepG2 (white
bars) and HepG2HNF‐4a‐sh (striped bars) cells as described above and
analysed by real-time PCR using the indicated primers. The mean and
standard errors of at least three independent experiments each
performed in triplicate are shown. Statistical significance was
determined by t test (two-tailed) analysis; ***p<0.001
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Fig. 3 HNF-4α production determines repressive histone modifica-
tions at the PED promoter. a, b Hela and HepG2 cells were
transfected with 1 μg of the pCDNA3/HNF-4α expression vector
and of the HNF-4α-specific shRNA clone, respectively. At 48 h after
transfection, total RNAs were extracted from transfected and non-
transfected cells. PED mRNA levels were then quantified by RT-PCR.
Data were normalised to β-actin mRNA and are expressed as per cent
decrease or increase vs control (untransfected cells). ChIP experiments
were performed using antibodies against active histone marks, i.e.
(c–f) acetyl-histone H3 and (g–j) H3K4me2, in the PED gene in HeLa
(black bars) and HeLaHNF4a cells (grey bars), and in HepG2 (white
bars) and HepG2HNF‐4a‐sh (striped bars) cells. ChIP was also
performed against the repressive histone mark H3K9me2 (k–n) in
HeLa and HeLaHNF‐4a cells, and in HepG2 and HepG2HNF‐4a‐sh cells.
ChIPs were followed by quantitative PCR amplification with primer
set for the C region of the PED promoter. Representative gels (d, f, h,
j, l, n) are shown. Levels in bar graphs (c, e, g, i, k, m) are presented
as per cent enrichment relative to input DNA and corrected for IgG
control levels as analysed by quantitative PCR. Bars represent the
mean ± SE of three independent experiments each performed in
triplicate. Statistical significance was assessed by t test analysis.
***p<0.001
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suggest that HNF-4α production and binding to the HRE
causes nucleosome positioning at C and D regions in the
proximal PED gene promoter.
HNF-4α induces histone deacetylation and methylation at
the PED promoter We next focused on the significance of
HNF-4α cellular levels for the epigenetic state of the PED
promoter region. To this end, we looked for typical
transcriptional activation and repression marks in the cells
with high (HeLaHNF‐4a, HepG2) and low (HeLa,
HepG2HNF‐4a‐sh) HNF-4α levels, in which PED transcrip-
tion is suppressed and active, respectively (Fig. 3a, b). ChIP
assays were performed using antibodies recognising histone
modifications, as well as normal rabbit IgG as a negative
control, with the purified DNA from the immunoprecipi-
tates being used for real-time PCR analysis with primer sets
amplifying the C region nucleosome. In HeLaHNF‐4a and
HepG2 cells we saw an almost twofold reduction in histone
H3 acetylation at lysines 9 and 14 (a mark of active
transcription) compared with HeLa and the HepG2HNF‐4a‐sh
cells (Fig. 3c, e). A further mark of active transcription
[30], lysine 4 dimethylated histone H3, was similarly
reduced in these cells (Fig. 3g, i). Also, the dimethylation
of histone H3 at lysine 9 (H3K9me2), a mark typical of
repressed gene promoters [31], was almost threefold higher
at the C region nucleosome from HeLaHNF‐4a and HepG2 as
compared with HeLa or HepG2HNF‐4a‐sh cells (Fig. 3k, m).
Similar results were obtained with the D region nucleosome
(data not shown). Thus, HNF-4α production and response
element binding is accompanied by enrichment in repres-
sive histone modifications together with reduced rate of
PED expression.
In addition, the HepG2HNF‐4a‐sh cells, which feature high
levels of PED mRNA, exhibited reduced hepatic glycogen
content compared with control cells. Similar results were
obtained in stably transfected HepG2 cells overexpressing
human PED (Fig. 4a).
We also analysed glycogen content in livers from PED
transgenic mice. These animals have been previously
characterised and described [26]. As shown in Fig. 4b, the
abundance of hepatic glycogen content was lower in
transgenic mice than in control non-transgenic littermates
(Fig. 4b).
HNF-4α recruits repressive enzymes at the PED promoter
and silences expression Since HNF-4α production results
in decreased histone acetylation, we investigated the
presence of histone-modifying enzymes at the HRE region
in thePED promoter in the presence and absence of HNF-4α.
Using ChIP assays, we demonstrated the presence of the
SMRT co-repressor complex at the HNF-4α in HepG2 cells
but not in Hela cells (Fig. 5a). Importantly, HeLa and HepG2
cells feature very comparable levels of SMRT, indicating that
the presence of SMRT at the HRE observed in the HepG2
cells is not dependent on SMRT levels (ESM Fig. 1a). The
assembly of HNF-4α/SMRT complexes on the PED promot-
er region was then investigated by Re-ChIP experiments
using HNF-4α antibody in the first ChIP and a SMRT
antibody in the second ChIP. As shown in Fig. 5b, c, we
detected HNF-4α together with SMRT at the HRE in
HeLaHNF‐4a and HepG2 cells, while the complex was barely
detectable in cells producing lower amounts of HNF-4α
(HeLa and the HepG2HNF‐4a‐sh). Nuclear extracts from each
cell type were immunoprecipitated with the SMRT antibody
and the immunocomplexes blotted with the HNF-4α
antibody. Again, we detected an HNF-4α/SMRT interac-
tion only in the HNF-4α-producing cells, HeLaHNF‐4a and
HepG2, compared with HeLa and HepG2HNF‐4a‐sh cells,
respectively (Fig. 5d), indicating that recruitment of the co-
repressor SMRT was entirely dependent on the presence of
HNF-4α.
Re-ChIP experiments using antibodies toward the re-
pressive histone mark H3K9me2 followed by HNF-4α or
SMRT antibodies revealed that levels of these complexes
were reduced in the cells with low HNF-4α levels
Fig. 4 Effect of PED overproduction on hepatocyte glycogen content.
a HepG2, HepG2HNF4ash and HepG2/PED cells were assayed for
glycogen content after incubation with 100 nmol/l insulin (black bars)
as described above. White bars, without insulin. b Glycogen content
was also compared in liver tissue from transgenic mice overexpressing
PED (Tg-PED) and from their non-transgenic littermates (BDF)
maintained under random-feeding conditions. Bars represent the
means ± SE of three (a) and four (b) independent measurements each
in triplicate. *p<0.05, **p<0.01 and ***p<0.001
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(HeLa and the HepG2HNF‐4a‐sh), in which PED transcrip-
tion is active. This finding indicates that HNF-4α/SMRT
assembly to the PED gene is accompanied by histone
deacetylation and methylation at its proximal promoter
(ESM Fig. 1b).
Since HNF-4α production results in changes of the
epigenetic state of chromatin, we investigated the possibil-
ity of activating the PED gene by pharmacological
inhibition of histone deacetylation. Incubation of HepG2
cells with the deacetylase inhibitor trichostatin A revealed
an increase in PED expression in these cells (Fig. 5e). Since
HNF-4α levels also significantly increased upon trichosta-
tin A treatment, we sought to verify whether hyper-
acetylation induced by trichostatin A treatment impairs
HNF-4α binding to its response element, as this effect may
have been sufficient to enhance PED transcription. We
found no difference in HNF-4α at its B region-amplified
response element in HepG2 cells, whether preincubated
with trichostatin A or not (ESM Fig. 2). This supports the
role of histone deacetylation in restraining PED activity. We
conclude that histone deacetylation is required for HNF-4α-
mediated PED repression.
SMRT silencing rescues PED expression in HepG2 cells To
further address the role of SMRT in HNF-4α-dependent
repression of PED function, HepG2 cells were transiently
transfected with siRNAs for SMRT (also known as
NCOR2)-α and SMRTβ (panSMRT) or a control siRNA
[25]. Real-time PCR assays on total RNA from panSMRT-
silenced HepG2 cells showed about twofold increased PED
RNA levels compared with control siRNA and wild-type
cells (Fig. 6a). Western blot analysis of extracts from the
different cell types also revealed significantly increased
PED and decreased SMRT protein levels upon the
panSMRT transfection (Fig. 6b). In addition, ChIP assays
in panSMRT-treated HepG2 cells using acetyl-histone H3
(K9/K14) and H3K9me2 antibodies showed significantly
increased acetylation and decreased methylation of the
histone H3 lysine 9 compared with controls (Fig. 6c).
The role of SMRT in HNF-4α regulation of PED
expression was further addressed in HepG2 cells trans-
fected with a PED promoter luciferase construct featuring
the HRE (pPED477). Co-transfection of the panSMRT
siRNA in these cells increased the pPED477 reporter gene
activity by twofold. Importantly, the luciferase activity of a
vector containing the mutagenised HNF-4α binding se-
quence (pPED477mut) abolishing its transcriptional activity
was increased at similar levels in control and panSMRT
transfected HepG2 cells (Fig. 6d) compared with HepG2
wild-type cells transfected with the pPED477 vector alone
(Fig. 6d). This indicates that the recruitment of HNF-4α
and SMRT to the HRE at the PED promoter is necessary
for PED transcriptional inhibition.
SMRT enables HNF-4α inhibition of GRB14 and USP21
genes To verify whether SMRT action on HNF-4α silenc-
ing is unique to the PED gene, we analysed expression of
the two other genes repressed by HNF-4α, GRB14 and
Fig. 5 Recruitment of repressive enzymes at the PED promoter is
dependent on HNF-4α. ChIP experiments were performed using
antibodies against SMRT (a) and HNF-4α (b, c). The binding of
SMRT to the HRE of PED was analysed by quantitative PCR in (a)
HeLa and HepG2 wild-type cells. HNF-4α binding was analysed by
quantitative PCR in the HRE of PED in HeLa (black bar) and
HeLaHNF‐4a (grey bar) (b), and (c) in HepG2 (white bar) and
HepG2HNF‐4a‐sh (striped bar) cells. Re-ChIP experiments were
performed using antibodies against SMRT (b, c) to identify protein
complexes at the HRE of PED. The amount of precipitated DNA from
the first ChIP was used as input. Results are expressed as enrichment
relative to input (%) and corrected for IgG control levels. d HeLa,
HeLaHNF‐4a , HepG2 and HepG2HNF‐4a‐sh cells were grown as
described and total lysates of the cells immunoprecipitated with
antibodies against SMRT and then analysed by immunoblot with
antibodies against HNF-4α and SMRT. Filters were revealed by ECL.
The autoradiograph shown is representative of four independent
experiments. e HepG2 cells were treated with 330 nmol/l trichostatin A
(black bars) for 24 h. White bar, vehicle. PED and HNF-4α expression
were determined by real-time PCR. Data were normalised to β-actin
levels and expressed as relative to vehicle treatments. Bars (a–c, e)
represent the mean ± SE of at least three independent experiments each
performed in triplicate. Statistical significance was assessed by t test
analysis. ***p<0.001
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USP21. Interestingly, GRB14 and USP21 were expressed at
reduced levels in the HeLaHNF‐4a compared with untrans-
fected cells (Fig. 7a). In addition, expression of these genes
was rescued by HNF-4α silencing in HepG2HNF‐4a‐sh cells,
further supporting the repressor function of HNF-4α
(Fig. 7b). The regulatory region of GRB14 and USP21
has not been reported yet. By in silico analysis, we
therefore identified their HREs at −700 and −450 bp
upstream of their transcriptional start sites, respectively
(Fig. 7c). ChIP and Re-ChIP assays with specific antibodies
and HRE primer sets revealed largely increased HNF-4α
and HNF-4α/SMRT complex abundance at the HRE in the
HeLaHNF‐4a compared with untransfected cells (Fig. 7d).
Consistently, the presence of HNF-4α and HNF-4α/SMRT
complex at the response element was significantly reduced
in HepG2 cells transfected with the HNF-4α-sh (Fig. 7e).
We then examined the acetylation state of the GRB14 and
USP21 proximal regulatory regions and performed ChIP
assays using acetyl-histone H3 (K9/K14) antibodies and
Fig. 7 HNF-4α-dependent inhibition of GBR14 and USP21 expres-
sion. Total RNA preparations were obtained (a) from HeLa (black bars)
and HeLaHNF‐4a (grey bars) cells, and (b) from HepG2 (white bars)
and HepG2HNF‐4a‐sh (striped bars) cells. Levels of GRB14 and USP21
mRNA were then determined by real-time PCR and normalised to
β-actin mRNA. mRNA levels are relative to those in control (HeLa,
HepG2) cells. c Schematic representation of the GRB14 and USP21
genes, with arrows indicating ChIP primers against the HNF-4α
binding site (HRE) and the region downstream the HRE. ChIP
experiments were performed using antibodies against HNF-4α (d, e)
and (f, g) active histone marks (acetyl-histone H3). HNF-4α binding
was analysed by quantitative PCR in the HRE of GRB14 and USP21 in
HeLa and HeLaHNF‐4a (d) and HepG2 and HepG2HNF‐4a‐sh (e) cells.
Acetyl-histone H3 enrichment at the GRB14 and USP21 regulatory
regions was analysed by quantitative PCR in HeLa and HeLaHNF‐4a (f),
and HepG2 and HepG2HNF‐4a‐sh (g) cells. Re-ChIP experiments were
performed using antibodies against SMRT (d, e) to identify protein
complexes at the HRE of GRB14 and USP21 genes. The amount of
precipitated DNA from the first ChIP was used as input. Results are
expressed as per cent enrichment relative to input DNA and corrected
for IgG control levels. Bars represent the mean ± SE of three
independent experiments each performed in triplicate. Statistical
significance was assessed by t test analysis. **p<0.01, ***p<0.001
Fig. 6 Effect of SMRT depletion on PED expression in HepG2 cells.
HepG2 cells were transfected with Silencer negative control siRNA
(grey bars) or siRNAs for panSMRT (black bars). a SMRT and PED
mRNA levels were quantified by real-time PCR. Data were
normalised to β-actin mRNA and are expressed as fold over control
(untransfected cells [NT], white bars). b Lysates prepared from HepG2
cells transfected with siRNAs were western-blotted with PED and
SMRT antibodies and further analysed by ECL and autoradiography.
The autoradiograph shown is representative of four independent
experiments. c ChIP experiments were performed using antibodies
against active (acetyl-histone H3 [AcH3]) or repressive (H3K9me2)
histone marks. Their binding was analysed by quantitative PCR in the
nucleosome C region of PED promoter in control or (panSMRT)
HepG2 cells and expressed as fold over control (untransfected cells).
d HepG2 cells were co-transfected with 3 μg of the indicated PED
promoter–luciferase constructs (or 3 μg of the promotorless pGL3
basic vector) alone or in combination with SMRTα and SMRTβ
siRNAs or the Silencer negative control siRNA and 1 μg of the
pRSVβ-gal vector DNA. Luciferase activity was assayed as
described and is presented as the increase above the activity
measured with the control pGL3 basic vector. Bars represent the
mean ± SE of three independent experiments each performed in
triplicate. Statistical significance was assessed by t test analysis.
***p<0.001
Diabetologia (2010) 53:1482–1492 1489
primer sets amplifying a 300 bp region downstream of the
HREs. Histone H3 (K9/K14) acetylation was significantly
reduced in the HeLaHNF‐4a, but rescued in the
HepG2HNF‐4a‐sh cells (Fig. 7f, g), indicating common
mechanisms in the silencing of the PED, GRB14 and
USP21 genes by HNF-4α.
Discussion
Previous work has established the significance of the
nuclear receptor superfamily in regulating a broad range
of cellular processes by activating or repressing different
sets of genes that harbour nuclear receptor-recognising
DNA motifs [32]. Several mechanisms leading to transcrip-
tional activation by the nuclear receptors have been
elucidated in considerable detail [33]. Against this, the
molecular bases of transcriptional repression remain more
unclear [34, 35].
In the present study, we show that HNF-4α, a member of
the steroid receptor class of nuclear receptors [36, 37],
triggers SMRT recruitment to the PED proximal promoter
and causes histone tail hypoacetylation at H3-K9/K14,
inducing a transcriptionally non-permissive state of the
gene. These changes are followed by the appearance of
H3K9 hypermethylation and H3K4 hypomethylation, two
marks of heterochromatin (Fig. 8). These findings indicate
for the first time that, in intact cells, HNF-4α represses
gene transcription by directly recruiting SMRT to the
promoter region, leading to histone deacetylation-
associated remodelling of chromatin.
Previous studies in HNF-4α-producing cells and in cells
with no HNF-4α production have shown that SMRT
represses HNF-4α-mediated transcription of reporter con-
structs containing heterologous, as well as native promoters
[38]. In addition, using glutathione S-transferase pull-down
assays, the same team of authors showed that HNF-4α
directly binds the receptor interacting domain 2 of SMRT in
vitro [38]. These observations suggest that SMRT repres-
sion might represent a physiologically relevant mechanism
responsible for HNF-4α regulation and that functional
cooperation requires physical interaction of SMRT and
HNF-4α. The finding we now report, namely that the HNF-
4α/SMRT complex induces GRB14 and USP21 repression
in addition to PED gene silencing, further underlines the
significance of these mechanisms to the in vivo transcrip-
tional repressor activity of HNF-4α.
HNF-4α has long been known to serve as a transcrip-
tional activator [39]. Indeed, HNF-4α can: (1) activate
transcription in the absence of exogenously added ligands
[40]; and (2), in mammalian cells, in yeasts and in vitro,
respond to several coactivators including glucocorticoid
receptor interacting protein 1 (GRIP1), steroid receptor
coactivator 1 (SRC-1) and CREB binding protein (CBP)-
p300 [41, 42]. However, Ruse et al. reported that HNF-4α
regulation by these coactivators can be competitively
abolished by interaction of the histone deacetylase-
associated co-repressor SMRTwith the F domain of HNF-4α
[38]. Thus, the nature of the recruited co-regulator and of its
association with direct effectors of histone modifications
such as histone deacetylases appears to determine the
transcriptional activity of HNF-4α.
Recently, it has been shown that a knock-in mouse bearing
a mutation in the receptor interacting domain of SMRT
(SMRTmRID) that disrupts its interaction with the nuclear
hormone receptor [43] develops multiple metabolic defects
including altered insulin sensitivity and 70% increased
adiposity. These findings indicate that major districts of
metabolic regulation such as insulin sensitivity and fat mass
depend on the molecular balance of co-repressors and
coactivators, which modulate the status of chromatin and
nuclear receptor signalling and ultimately regulate gene
expression in response to specific physiological situations.
PED expression is upregulated in individuals with type 2
diabetes and in the euglycaemic offspring of these patients,
impairing insulin action and insulin secretion [5, 7]. However,
the causes for PED upregulation required additional investi-
gation. In the present study, we demonstrated that HNF-4α
silencing alters the epigenetic state of the PED gene and
determines its overexpression in liver cells. We further show
that induction of PED gene expression in hepatocytes is
paralleled by reduced hepatic glycogen content. We have also
very recently demonstrated that activation of PED expression
in HepG2 cells is paralleled by the establishment of a
partially dedifferentiated phenotype, accompanied by reduced
mRNA levels of genes expressed during normal liver
development [11]. Thus HNF-4α-regulated PED gene may
have a role in hepatocyte differentiation. Epigenetic changes
upregulating its expression might impair development of
normal liver function, thereby contributing to progression
toward diabetes. Environmental factors have been reported to
induce epigenetic changes, leading to the development of
Fig. 8 Epigenetic changes induced by HNF-4α to PED expression.
HNF-4α production and binding to its response element causes
chromatin packaging at the PED promoter and enrichment of histone
H3 methylation at lysine 9 (H3K9me2), a mark typical of repressed
gene promoters. HRE binding also causes a decrease in acetylation at
lysine 9 and 14 (AcH3K9/K14) and dimethylation of lysine 4 of
histone H3 (H3K4me2), two marks of active transcription
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abnormal phenotypes [44, 45]. For instance, diet and ageing
have been reported to perturb gene expression by inducing
DNA methylation and histone modifications [46]. Also,
intrauterine growth retardation, a common complication of
pregnancy, has been associated with later development of
type 2 diabetes, in part through chromatin remodelling effects
and epigenetic modulation of the expression of several genes
[47]. Type 2 diabetes is a genetically heterogeneous disease
resulting from complex interactions of genetic and environ-
mental determinants. Previous studies using different
approaches have uncovered a number of type 2 diabetes
susceptibility genes, but it remains less clear how these genes
determine type 2 diabetes. In particular, the molecular details
of gene–environment interplay in diabetes onset have
received less attention. Exposure to certain environmental
determinants, including maternal obesity [48], intrauterine
environment [49, 50] and nutritional factors [51], affects key
developmental sequences programming metabolic respon-
siveness to environmental stimuli during later life. Such
concepts are now supported by studies of monozygotic twins,
where diabetes risk is discordant and linked to birthweight
[52]. Laboratory studies are in progress to assess whether
PED may serve as an environment gene target contributing to
type 2 diabetes progression.
In conclusion, in the present work, we demonstrate that
HNF-4α inhibits PED expression by inducing chromatin
remodelling and histone modifications at nucleosomes
located in the regulatory region of the gene. Dysregulation
of these mechanisms might promote pathogenetic sequen-
ces leading to type 2 diabetes.
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